

INDEX

- AB1-42:
Alzheimer's disease, invertebrate models,
579–582
- ABT-418 nicotinic agonist:
dementia disorders and, 467–468
- ACEA 1021/1031 agents:
stroke management, 358
- Acetylcholinesterase inhibitors:
dementia disorders and, 463–465
- Acquired immunodeficiency syndrome
(AIDS):
alcohol abuse and, 716
cholinergic system, 711–712
clinical features, 694–695
dementia and, 711–712
drug abuse and, 712–716
methamphetamine/cocaine, 713–715
opioid drugs, 715–716
excitatory amino acid neurotransmitters,
711
future neuropharmacology issues, 718
lipid metabolism alterations, 707
neurodegenerative diseases and, 716–718
neuropathology, 695–704
cell death cascades, 704–707
apoptosis, 704–705
excitotoxicity, 705–706
neural progenitor cells, 706–707
oxidative stress, 706
chemokines in, 697–698
neurodegenerative mechanisms, 699
neuropharmacology
features of, 694–695
neurotoxic proteins, 699–704
glycoproteins gp120 and gp41, 699,
701
Nef protein, 703
neurobiology of, 700
Rev protein, 704
Tat protein, 701–703
Vpr protein, 703
Vpu protein, 704
nigrostriatal system, 707–711
dopamine mediators, 709–711
pathogenesis, 695
- Acute motor axonal neuropathy (AMAN):
pathology, 614
- Acylated peptide hormones:
ghrelin receptor ligands, 766–768
- Adaptor proteins:
tyrosine kinase receptor signaling,
243–245
- Addictive disorders:
hypocretin/orexin system, 135
- Adenosine A_{2A} receptors:
neuroinflammation
purinergic receptor modulation and,
643–644
Parkinson's disease treatment, 505–506
- Adenosine deaminase (ADA) deficiency:
neuroinflammation and, 643–644
- Adenosine triphosphate (ATP):

- adipose tissue cell types and depots, 786–789
- ischemic brain injury, 351–353
- Adenylyl cyclase:
 - adipose tissue signaling and, 802–803
- Adhesion molecules:
 - inflammation mechanisms, 624–625
- Adipocytes:
 - ghrelin modulation, 775
 - leptin secretion and, 735–736
 - proliferation, sympathetic nervous system innervation and, 797–799
 - white vs. brown molecular features, 787–789
- Adipose tissue:
 - catecholamine signaling mechanisms, 801–803
 - cell types and depots, 786–789
 - future research issues, 804
 - glyceroneogenesis, 799–801
 - sympathetic nervous system innervation, 789–797
 - adipocyte proliferative capacity, 797–799
 - anterograde tract-testing, SNS to WAT, 792–797
 - retrograde tracing neuroanatomical studies, 790–792
 - white vs. brown adipocytes, 787–789
- Adrenergic agonists:
 - attention-deficit hyperactivity disorder therapy, 299–300
 - autism spectrum disorders, 330
 - Tourette's syndrome therapy, 276–277
- Adrenergic neurotransmitters:
 - cataplexy therapy
 - animal models, 109–110
- Adrenocorticotropin hormone (ACTH):
 - for secondary generalized epilepsy, 424
- Adrenoreceptors:
 - white adipose tissue innervation, 789–797
- Adult respiratory distress syndrome (ARDS):
 - adenosine pathway and purinergic receptor modulation, 644
- Advanced sleep phase syndrome (ASPS):
 - circadian rhythms, melatonin receptor modulation, 58
- AF102B agonist:
 - dementia disorders and, 466
- Affective disorders:
 - autism spectrum disorder and, 333
 - circadian rhythms and, 15–17
- Afferent neurones:
 - hypocretins at, 130
- Aftereffects:
 - circadian rhythms, 6
- Age of onset modifiers:
 - idiopathic Parkinson's disease, 542
- Aggression:
 - autism spectrum disorders, 334
- Agomelatine:
 - melatonin receptor targeting, 57–58
 - depression therapy, 59–61
- Agouti-related peptide (AgRP):
 - antiobesity therapy
 - axokine, 823–824
 - hypocretin/orexin system and, 132–134
- Alcohol abuse:
 - HIV neuropharmacology and, 716
 - idiopathic Parkinson's disease and, 544
- ALE-0540:
 - nerve growth factor inhibitor, 232
- Alemtuzumab:
 - multiple sclerosis therapy, 677–679, 686
- Alzheimer's disease:
 - diagnostic criteria, 462
 - invertebrate models, 579–582
 - neuropathies and, 227–228
- Alzheimer's disease (AD):
 - acetylcholinesterase inhibitors and, 463–465
 - glutamate receptor ligands, 469–471
 - muscarinic receptor drugs and, 465–469
 - nicotinic agonists, 469
 - therapeutic targets, 471–473
- Amantadine:
 - autism spectrum disorders, 332
 - Parkinson's disease treatment, 496–497
- α -Amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA):
 - antiepileptic drugs and topiramate, 416–417
 - dementia disorders and, 470
 - neurogenesis and, 208
 - neurotrophic factor synthesis and, 232
 - stroke and
 - ischemic brain injury, 351–353
 - receptor antagonists, 361–363
- Amisulpiride:
 - Tourette's syndrome therapy, 276
- AMP-activated kinase (AMPK):
 - ghrelin effects and, 773

- Amphetamines:
 attention-deficit hyperactivity disorder therapy, 296–298
 narcolepsy therapy
 adverse effects, 98
 cerebrospinal fluid hypocretin-1 assessment, 84
 drug interactions, 98, 100
 excessive daytime sleepiness and, 90–100
 histocompatibility human leukocyte antigen testing, 84
 molecular targeting, 93–94
 polysomnography, 83
 stroke therapy and, 377
 traumatic brain injury and, 453–454
- β -Amyloid peptide:
 in HIV patients, 717–178
 neurodegenerative disease immunization modulation of, 644–645
- Amyloid precursor protein (APP):
 Alzheimer's disease, invertebrate models, 579–582
 in HIV patients, 717–178
- Amyotrophic lateral sclerosis (ALS):
 neurotrophic factor therapy and, 225–227
- Anesthesia:
 hypocretin/orexin system, 136
- Angiogenesis:
 prokineticins and, 169–170
- Animal models:
 antiepileptic drugs
 topiramate, 416–417
 circadian rhythms
 mammalian models, 10–13
 nonmammalian models, 6–9
 human autoimmune neuropathies, 615
 invertebrate models
 neurodegenerative disease:
 Alzheimer's disease, 579–582
Caenorhabditis elegans system, 568–569
Drosophila melanogaster, 569
 early research, 567–568
 future applications, 582–583
 genetic and molecular pathways, 568
 Huntington's disease trinucleotide repeats, 577–579
 Parkinson's disease
 dopamine neuron cell death, 569–577
 myelin disorders
 experimental allergic encephalomyelitis, 611–612
 narcolepsy
 hypocretin-1 deficiency, 86
 modafinil therapy, 102–103
 stroke and
 global and focal ischemia, 353–354
 NMDA receptor antagonists, 355–356
- Anterograde tract-tracing:
 sympathetic nervous system innervation
 white adipose tissue, 792–797
- Antiadhesion molecules:
 stroke management, 369–370
- Antiapoptotic signaling:
 p75 neurotrophin receptor, 246–247
- Anticholinergic agents:
 Parkinson's disease treatment, 496, 502
- Anticonvulsant drugs. *See also* Antiepileptic drugs (AEDS)
- Antidepressants:
 cataplexy therapy, 114–115
 historical overview, 106–107
 second- and third-generation, 108
 tricyclic antidepressants, 107–109
 circadian rhythms and, 18–20
 melatonin receptors, therapeutic targeting of, 58–61
 neurogenesis and, 209–210
 sleep effects of, 17–18
- Antiepileptic drugs (AEDs). *See also* Anticonvulsant drugs
 autism spectrum disorder therapy, 332–333
 epilepsy, 404–405
 calcium channels, 413–414
 clinical efficacy, 417–418
 clinical prediction markers, 420
 combination therapy, 423–424
 development and testing, 418–420
 felbamate interactions, 414–415
 GABA_A receptor and, 411–412
 generalized absence epilepsy, 421
 localization-related epilepsy, 421–423
 mechanisms of action, 408–410
 metabotropic glutamate receptors, 413
 mixed actions, 414–418, 422
 secondary generalized epilepsies, 424
 selection criteria, 421–424
 sodium channel modulation, 411
 special population requirements, 424–425

- synaptic vesicle protein, 414
- topiramate interactions, 415–418
- toxicity detection, limitations of, 420–421
- molecular targeting, 409–410
- pharmacokinetic characteristics, drug interactions and serum levels, 422
- Antigen-presenting cells (APC):
 - neuroinflammation, 626
 - astrocytes and, 627
- Antigen-specific T cells:
 - inflammation mechanisms, 625
- Antiglutamate agents:
 - Parkinson's disease treatment, 496–497
- Antihistamines:
 - sedative/hypnotics and, 188
- Anti-inflammatory agents:
 - stroke management, 367–371
 - traumatic brain injury and, 447–449
- Anti-NoGo agents:
 - stroke therapy, 377–378
- Antiobesity agents:
 - current development of, 821–831
 - axokine, 822–824
 - CCK_A receptor agonists, 830–831
 - future research issues, 831–833
 - MC4 receptor agonists, 828–829
 - MCH receptor-1 antagonists, 829–830
 - orlistat, 820–821
 - PYY3-36 peptide agonists, 831
 - rimonabant, 824–828
 - serotonin receptor 5-HT_{2C} agonists, 828
 - FDA-approved drugs, 819
 - future research issues, 832–833
 - historic perspective on, 817–818
 - orlistat, 820–821
 - sibutramine, 818–820
- Antioxidants:
 - neuroinflammation and, 636–637
 - Parkinson's disease therapy, 504–505
 - stroke management, 371–372
- Antiproliferative/proliferative mechanisms:
 - ghrelin modulation, 776
- Antipsychotic agents:
 - attention-deficit hyperactivity disorder therapy, 301
 - autism spectrum disorders
 - atypical agents, 326–330
 - typical agents, 325–326
- Anxiety and anxiety disorders:
 - Parkinson's disease treatment and, 500–501
- Aplysia californica*:
 - circadian rhythmicity, 9
- Apomorphine:
 - Parkinson's disease treatment, 493–494, 505
- Apoptosis mechanisms:
 - HIV neuropathology, 704–705
 - neuroinflammation and modulation of, 637–638
 - stroke management, 372–373
- Appetite regulation:
 - ghrelin effects, 772–773
 - hypocretin/orexin system, 132–134
 - leptin signaling and, 740–743
 - prokinetics and, 168–169
- Arachidonic acid pathways:
 - neuroinflammation and, 630
 - pharmacological activation of, 634–635
- Aripiprazole:
 - autism spectrum disorders, 327–328
- AR juvenile parkinsonism:
 - parkin* gene mutations and, 530–532
- Aromatic amino acid decarboxylase (AADC):
 - Parkinson's disease neurochemistry, 481–483
- Arousal:
 - hypocretin/orexin system, 139–144
 - cholinergic systems, 143–144
 - dopaminergic systems, 143
 - feeding and motivation integration, 144
 - histaminergic systems, 142–143
 - lateral hypothalamic neurons, 140–141
 - noradrenergic systems, 141–142
 - serotonergic systems, 142
 - sleep and circadian rhythms:
 - chronopharmacology, 15–23
 - functional importance, 4
 - future research issues, 23–24
 - mammalian structural models, 10–13
 - nonmammalian structural models, 6–10
 - properties, 4–6
 - superchiasmatic nucleus period and phase, 13–15
- Artemin (ARTN):
 - discovery of, 221–223
- Aschoff's rules:
 - circadian rhythms, 5–6

- Astrocytes:
 HIV neuropathogenesis and, 697
 neuroinflammation and, 627
 cytokine/chemokine expression, 632
- Ataxin-3:
 Huntingdon's disease, invertebrate model, 578–579
- Atomoxetine:
 attention-deficit hyperactivity disorder therapy, 299
- Atorvastatin:
 multiple sclerosis therapy, 667
- Attention-deficit hyperactivity disorder (ADHD):
 clinical management issues, 301–302
 diagnostic criteria, 291–292
 evaluation, 292–293
 pharmacotherapy, 293–301
 adverse effects, 298
 amphetamines, 296–298
 antipsychotics, 301
 atomoxetine, 299
 bupropion, 300–301
 clonidine/guanfacine, 299–300
 dexmethylphenidate, 296
 methylphenidate hydrochloride, 294–296
 modafinil, 301
 nonstimulants, 299–301
 stimulants, 293–298
 tricyclic antidepressants, 299
 venlafaxine, 301
- Tourette's syndrome comorbidity, 266–268, 276–277
- treatment rational, 292
- Autism spectrum disorders:
 aggression/self-injury, 334
 anxiety and depression, 334
 interfering repetitive behaviors, 334
 motor hyperactivity and inattention, 333–334
 overview, 320–321
 pharmacology, 321–333
 adrenergic agonists, 330
 amantidine, 332
 antiepileptic drugs, 332–333
 antipsychotics, 325–328
 atypical antipsychotics, 326
 clomipramine, 322
 clonidine, 330
 clozapine, 326
 d-cycloserine, 332
 dopaminergic medications, 325–330
 fluoxetine, 323–324
 fluvoxamine, 322–323
 glutamatergic medications, 331–332
 guanfacine, 330–331
 haloperidol, 325
 lamotrigine, 332
 methylphenidate, 329–330
 mirtazapine, 331
 olanzapine, quetiapine, ziprasidone, and aripipazole, 327–328
 pimozide, 325–326
 risperidone, 326–327
 serotonergic medications, 321–325
 sertraline, citalopram, escitalopram, and paroxetine, 324–325
 stimulants, 328–330
 venlafaxine, 331
 syndromes within, 333–335
- Autoimmune disorders:
 demyelinating disorders of PNS, 613–615
 human autoimmune neuropathies, 613–614
 Tourette's syndrome and, 268–269
- Autonomic effects:
 hypocretin/orexin system, 134–135
- Autosomal-dominant (AD) Parkinsonism:
 genetic mutations in, 527
- Autosomal-recessive (AR) Parkinsonism:
 genetic mutations in, 527
- Avonex:
 multiple sclerosis therapy, 684–685
- Axokine:
 antiobesity therapy, 822–824
- B7 molecule:
 inflammation and, 631
- Baclofen:
 Tourette's syndrome, 277
- Barbiturates:
 as epilepsy therapy, 423
 GABA_A receptor binding site, 181
 structure and function, 184–187
- Basal ganglia:
 Parkinson's disease
 neurochemistry, 482–483
 Tourette's syndrome, 269–270
- Bcl-2 family proteins:
 stroke management, 373
- Behavior inhibition/activity:
 autism spectrum disorders, 334
 hypocretin/orexin system, 144

- melatonin modulation of circadian rhythms, 54–57
- Tourette's syndrome therapy, 277–278
- Benserazide:
 - Parkinson's disease treatment, 484–487
- Benzedrine:
 - attention-deficit hyperactivity disorder therapy, 296–298
- Benzhexol:
 - Parkinson's disease treatment, 496
- Benzodiazepines:
 - circadian rhythms and, 20–21
 - epilepsy efficacy, 417–418
 - as epilepsy therapy, 423
 - GABA_A receptor binding site, 180–181
 - sedative/hypnotic functions, 187–188
 - stroke management, 362
- Benztropine:
 - Parkinson's disease treatment, 496
- Betaseron:
 - multiple sclerosis therapy, 674–675
- Biological antagonists:
 - neurotrophic factors as, 231
- Blood-brain barrier (BBB):
 - HIV neuropathogenesis and, 696–697
 - inflammation and, 624–625
 - pharmacological activation, 633
- Blood-derived inflammatory cells:
 - neuroinflammation, 628
- BMAL1 protein:
 - circadian rhythms
 - animal models, 12
 - melatonin receptors and, 50–51
- Body composition:
 - ghrelin modulation, 775
- Bone morphogenetic proteins (BMP):
 - stroke and, 375–377
- Bone resorption and formation:
 - ghrelin modulation, 776
- Brain:
 - immunoreceptors, inflammation and, 631–632
 - sedative/hypnotic action sites in, 181–184
- Brain-derived neurotrophic factor (BDNF):
 - amyotrophic lateral sclerosis and, 226–227
 - cognitive function and, 228
 - depression and, 229–230
 - discovery of, 221–223
 - HIV neuropathology
 - Tax protein and, 705
 - indirect modulators of, 232
 - neurogenesis and, 206, 224
 - neuroinflammatory mechanisms, 641
 - neuronal maturation regulation, 224
 - neurotrophins and, 238
 - obesity and weight control, 229–230
 - p75 neurotrophin receptor signaling, 246–247
 - pain perception and management, 229
 - Parkinson's disease and, 228–229
 - structure of, 240
 - synaptic function and, 239
- Brain injury:
 - neurotrophic factors and, 229–230
 - stroke and
 - classification, 350
 - mechanisms of, 351–353
 - poststroke repair approaches, 375–379
 - repair approaches, 377–379
 - traumatic
 - characteristics and classification, 443–446
 - future research issues, 454
 - neural regeneration, 452–453
 - neuroplasticity, 453–454
 - neuroprotective agents, 446–451
 - anti-inflammatory agents, 447–449
 - free-radical scavengers, 447
 - neuroactive steroids/neurosteroids, 450–451
 - neurotransmitter agonists/antagonists, 449–450
- Breast cancer resistance protein (BCRP):
 - drug-resistant epilepsy, 425–426
- Bromocriptine:
 - Parkinson's disease treatment, 488, 490
- Brown adipose tissue (BAT):
 - classification, 786–789
 - glyceroneogenesis control, lipolysis and thermogenesis, 799–801
 - leptin and energy expenditure, 744
 - molecular features, 787–789
- Bupropion:
 - attention-deficit hyperactivity disorder therapy, 300–301
 - narcolepsy therapy, 103–104
- CAAT-enhancing binding proteins (C/EBP):
 - leptin secretion and expression of, 735–736
- Cabergoline:
 - Parkinson's disease treatment, 491
- Caenorhabditis elegans*:
 - neurodegenerative disease model

- Alzheimer's disease, 580–582
 - genetic and molecular pathways, 568–569
- Huntingdon's disease trinucleotide repeats, 577–579
- Parkinson's disease cell death, 570–577
- Caffeine:
 - idiopathic Parkinson's disease and, 544
 - narcolepsy therapy, 104–105
 - Parkinson's disease and, 505
- Calcium channels:
 - hypocretin/orexin system, 132
 - neuroinflammation and, 642
 - stroke and
 - ischemic brain injury, 351–353
 - neuronal channel blockers, 366–367
 - subunits
 - antiepileptic drug modulation, 413–414
 - suprachiasmatic nucleus, 13–15
 - T-type
 - antiepileptic drug modulation, 413
- cAMP response element binding (CREB) protein:
 - cognitive function and, 228
 - HIV neuropathology and apoptosis and, 705
 - Huntingdon's disease, invertebrate model, 579
 - leptin secretion and expression of, 735–736
 - melatonin receptors
 - supersensitization, 54
- Cannabinoid receptors:
 - antiobesity therapy, 825–828
 - neuroinflammation and modulation mechanisms, 641–642
- Carbamazepine:
 - development and testing, 419
 - epilepsy efficacy, 417–418
 - focal/localization-related epilepsy therapy, 421, 423
- Carbidopa:
 - Parkinson's disease treatment, 484–487
- Carbonic anhydrase:
 - topiramate and, 416–417
- Cardiovascular system:
 - ghrelin effects, 774–775
- Caspase inhibitors:
 - HIV neurotoxicity
 - Vpr protein, 703
 - stroke management, 372–373
- Cataplexy:
 - defined, 82
 - mazindol therapy, 103
 - narcolepsy pathophysiology, 85
 - human leukocyte antigen and, 85–86
 - pharmacological treatment
 - antidepressants, 114–115
 - future anticataplectics, 113–114
 - historical overview, 106–107
 - monoamine oxidase inhibitors, 111
 - neurotransmission, animal studies, 109–110
 - receptor subtypes, 110–111
 - second- and third-generation antidepressants, 108
 - sodium oxybate, 112
 - tricyclic antidepressants, 107–109
- Catecholamine signaling:
 - in adipose tissues, 801–803
- Catechol-*O*-methyl transferase (COMT):
 - Parkinson's disease
 - neurochemistry, 481–483
- CCK_A receptor agonist:
 - antiobesity therapy, 830–831
- CD9 protein:
 - structure and function, 608–609
- CD40 molecule:
 - inflammation and, 631
- CD80 molecule:
 - inflammation and, 631
- CD86 molecule:
 - inflammation and, 631
- Cell autonomy:
 - Circadian rhythmicity, 8
- Cell death cascades:
 - human immunodeficiency virus
 - neuropathology, 704–707
 - apoptosis, 704–705
 - excitotoxicity, 705–706
 - neural progenitor cells, 706–707
 - oxidative stress, 706
- Cellular migration:
 - neural inflammation and pharmacological activation, 633
- Central nervous system (CNS):
 - HIV neuropathogenesis and, 696–697
 - inflammation mechanisms in, 622–625
 - melatonin receptors
 - circadian rhythm modulation, 54–57
 - clock genes and, 50–51
 - desensitization, 52–53

- historical perspective, 38–40
- melatonin production, 40–41
- molecular pharmacology, 42–44
- molecular structure, 41–42
- overview, 37–38
- regulatory mechanisms, 51–54
- signaling mechanisms, 44–46
- supersensitization, 54
- suprachiasmatic nucleus, 46–54
 - circadian inputs and outputs, 46–47
 - receptor localization, signaling, and function, 47–50
- as therapeutic targets, 57–61
 - circadian rhythms, 58
 - depression, 58–61
 - sleep, 57–58
- CEP-1347 compound:
 - Parkinson's disease and, 229
- Ceramide production:
 - HIV lipid metabolism and, 707
- Cerebroside/sulfatide lipids:
 - in myelin, 594–596
- Cerebrospinal fluid (CSF):
 - hypocretin/orexin system
 - narcolepsy and, 138–139
 - narcolepsy evaluation
 - hypocretin-1 assessment, 84
- Cerostat/Aptiganel:
 - stroke management, 359
- Cerovive:
 - stroke management, 371–372
- Charcot-Marie-Tooth:
 - neurotrophic factor therapy, 227
- Chemokines:
 - HIV neuropathogenesis and, 697–699
 - inhibitors
 - stroke management and, 369
 - neuroinflammation and, 629–632
 - receptor-directed pharmacological approaches to, 633–634
- Chemotherapy:
 - multiple sclerosis
 - mitoxantrone, 676–677
- Cholecystokinin (CCK):
 - antiobesity therapy, 830–831
 - leptin signaling and feeding regulation, 743
- Cholesterol:
 - in myelin, 594–596
- Choline acetyltransferase:
 - HIV-associated dementia and, 711–712
- Cholinergic systems:
 - hypocretin/orexin system
 - arousal mechanisms, 143–144
 - neurogenesis and, 208–209
- Chromosome mapping:
 - hypocretin/orexin system, 127
- Chronic inflammatory demyelinating polyneuropathy (CIDP):
 - myelin pathology, 613–614
- Chronopharmacology:
 - circadian rhythms, 15
- Ciliary neurotrophic factor (CNTF):
 - amyotrophic lateral sclerosis, 226–227
 - antiobesity therapy
 - axokine, 822–824
 - depression and, 229–230
 - therapeutic applications, 226
- Circadian rhythms:
 - antidepressant effects on, 18–20
 - chronopharmacology, 15–23
 - functional importance, 4
 - future research issues, 23–24
 - mammalian structural models, 10–13
 - melatonin receptor modulation, 54–57
 - therapeutic targeting, 58
 - neurotrophins and, 239
 - nonmammalian structural models, 6–10
 - prokineticin regulation, 167–168
 - properties, 4–6
 - superchiasmatic nucleus
 - inputs and outputs, 46–47
 - period and phase, 13–15
- Cisplatin-induced neuropathy:
 - neurotrophic factors and, 227
- Citalopram:
 - autism spectrum disorders, 324–325
- Claudin protein family:
 - structure and function, 608
- "Clinically isolated syndrome" (CIS) of demyelination:
 - betaseron therapy and, 675
- Clinical markers:
 - antiepileptic drug efficacy, 420
- Clock genes:
 - melatonin receptors and, 50–51
 - supersensitization function, 54
 - prokineticin regulation, 167–168
- Clock neurons:
 - synchronization and modulation, 8–9

- CLOCK protein:
 circadian rhythms
 animal models, 12
 melatonin receptors and, 50–51
- Clomipramine:
 attention-deficit hyperactivity disorder therapy, 299
 autism spectrum disorders, 322
- Clonazepam:
 Parkinson-related sleep disturbance, 504
- Clonidine:
 attention-deficit hyperactivity disorder therapy, 299–300
 autism spectrum disorders, 330
 circadian rhythms and, 19–20
 Tourette's syndrome therapy, 274–276
- Clozapine:
 autism spectrum disorders, 326
- CNS 1102 antagonist:
 stroke and, 357
- Cocaine:
 HIV/AIDS and, 713–715
- Cocaine- and amphetamine-regulated transcript (CART) peptides:
 antiobesity therapy
 axokine, 823–824
 leptin signaling and feeding regulation, 741–743
- Cockroach:
 circadian rhythms in, 10
- Coenzyme Q₁₀:
 Parkinson's disease treatment, 504–505
- Cognitive function. *See also* Dementia in HIV patients, 717–718
 neural system diversity and, 461–463
 neuropathies and, 227–228
 traumatic brain injury and, 446
- Comorbid conditions:
 Tourette's syndrome, 266–268
- Connexins:
 structure and function, 609
- Conotoxins:
 stroke management
 calcium channel blocker, 366–367
- Constipation:
 Parkinson's disease and, 503
- Cortical neurons:
 HIV neuropathology
 apoptosis and, 705
 Tourette's syndrome, 270
- Corticosteroids:
 multiple sclerosis acute relapse, treatment of, 672–673
 neurogenesis and, 206–207
 traumatic brain injury and, 448–449
- Corticotropin-releasing factor (CRF):
 hypocretin/orexin system, 135
- Cortisol:
 circadian rhythms and release of, 19–20
- Costimulatory molecules:
 inflammation and, 631
- Cryptochrome genes:
 melatonin receptors, 50–51
- Cyclic adenosine monophosphate (cAMP):
 melatonin receptors
 supersensitization, 54
 neuroinflammation and
 modulating agents, 635–636
- Cyclic guanosine monophosphate (cGMP):
 neuroinflammation and
 modulating agents, 635–636
- 2',3'-Cyclic nucleotide 3'-phosphodiesterase (CNP):
 structure and function, 603–604
- Cyclooxygenase (COX1) inhibitors:
 neuroinflammation
 arachidonic acid/prostaglandin pathways, 634–635
- Cyclooxygenase (COX2) inhibitors:
 neuroinflammation
 arachidonic acid/prostaglandin pathways, 634–635
 traumatic brain injury and, 448–449
- d*-Cycloserine:
 autism spectrum disorders, 332
- Cysteines:
 melatonin receptor molecular structure, 42
- Cytochrome P450:
 Tourette's syndrome therapy, 274–276
- Cytokines:
 circadian rhythms and, 21–23
 multiple sclerosis therapy
 daclizumab agents, 685–686
 neuroinflammation
 arachidonic acid pathways, 630
 astrocytes and, 627
 minocycline inhibition and, 645–646
 proinflammatory pathway modulation, 638–639
 receptor-directed pharmacological approaches to, 633–634
 structure and function, 628–629

- stroke and
 - ischemic brain injury, 352–353
 - stroke management and inhibition of, 368–369
 - traumatic brain injury and, 447–449
- D₂/D₃ receptors:
 - cataplexy therapy, 110–111
 - novel antikataplexics, 113–114
 - Tourette's syndrome therapy, 276
- Daclizumab:
 - multiple sclerosis therapy, 685–686
- Dardarin mutation:
 - familial Parkinson's disease and mutation of LRRK2 gene and, 538–539
- Daytime sleep studies:
 - narcolepsy evaluation, 83
- D-CPP-ene NMDA antagonist:
 - stroke management and, 356–357, 360
- Death domain:
 - p75 neurotrophin receptor structure and, 241
 - stroke management, 373
- Decahydroisoquinolines:
 - stroke management, 362
- Decarboxylase inhibitor:
 - Parkinson's disease treatment
 - levodopa with, 484–487
- Deep sleep phase syndrome (DSPS):
 - circadian rhythms, melatonin receptor modulation, 58
- Dementia:
 - acetylcholinesterase inhibitors and, 463–465
 - glutamate receptor ligands, 469–471
 - HIV-associated (HAD)
 - classification, 694–695
 - muscarinic receptor drugs and, 465–469
 - nicotinic agonists, 469
 - Parkinson's disease and, 502
 - therapeutic targets, 471–473
- L-Deprenyl:
 - narcolepsy therapy, 104
- Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP), 504–505
- Depression:
 - autism spectrum disorders, 334
 - melatonin receptors, therapeutic targeting of, 58–61
 - neurotrophic factors and, 229–230
 - Parkinson's disease treatment and, 500–501
- Desensitization:
 - melatonin receptors, 52–53
- Desipramine:
 - attention-deficit hyperactivity disorder therapy, 299
- Dexmethylphenidate:
 - attention-deficit hyperactivity disorder therapy, 296
- Diet:
 - epilepsy management and, 427
- Diethylpropion:
 - as anti-obesity agent, 817–818
- Dihydroergocryptine:
 - Parkinson's disease treatment, 491
- 3,4-Dihydroxyphenylacetic acid (DOPAC):
 - human immunodeficiency virus
 - methamphetamine/cocaine abuse and, 714–715
 - nigrostriatal system and, 709
 - Parkinson's disease
 - neurochemistry, 481–483
- Diphasic dyskinesia:
 - Parkinson's disease treatment and, 499
- Disturbed nocturnal sleep:
 - treatment of, 112
- DJ-1* gene:
 - familial Parkinson's disease and, 535–536
- Donepezil:
 - dementia disorders and, 464–465
- Dopamine agonists:
 - human immunodeficiency virus and
 - nigrostriatal system, 708–710
 - Parkinson's disease treatment, 488–494
 - antioxidant effects, 504–505
 - apomorphine, 493–494
 - bromocriptine, 488, 490
 - cabergoline, 491
 - monoamine oxidase type B inhibitor, 494
 - pergolide, 490–491
 - piribedil, 493
 - pramipexole, 491–492
 - ropinirole, 492
 - pharmacology of, 489
- Dopamine neurotransmitters:
 - hypocretin/orexin system
 - arousal mechanisms, 143
 - narcolepsy therapy
 - amphetamine targeting, 92–94
 - adverse effects, 98

- anatomical substrates, 97–98
 - drug interactions, 98, 100
 - EEG arousal and, 94–97
 - modafinil, 102–103
- Parkinson's disease neurochemistry and, 481–483
 - invertebrate models of cell death, 569–577
- Tourette's syndrome, 270–273
- Dopaminergic receptors:
 - autism spectrum disorders
 - medications, 325–330
 - human immunodeficiency virus nigrostriatal system and, 710–711
 - opioid abuse and, 715–716
 - Tourette's syndrome, 266–267
- Dopamine transporters:
 - attention-deficit hyperactivity disorder therapy, 297–298
- Dopaminomimetic agents:
 - Parkinson's disease, 484–496
 - apomorphine, 493–494
 - bromocriptine, 488, 490
 - cabergoline, 491
 - COMT inhibitors, 495
 - dihydroergocryptine, 491
 - dopamine agonists, 488–494
 - entacapone, 496
 - levodopa plus peripheral decarboxylase inhibitor, 484–487
 - levodopa slow-release formulations, 487–488
 - lisuride, 491
 - monoamine oxidase type B inhibitor, 494
 - pergolide, 490–491
 - piribedil, 493
 - pramipexole, 491–492
 - rasagiline, 495
 - ropinirole, 492
 - selegiline, 494–495
 - stalevo, 496
 - tolcapone, 495
- Dose failure:
 - Parkinson's disease treatment and, 499
- Downstream techniques:
 - stroke management, 366–373
- Drosophila* models:
 - Alzheimer's disease, 580–582
 - drug effects in, 7–8
 - Huntingdon's disease trinucleotide repeats, 578–579
 - neurodegenerative disease
 - genetic and molecular pathways, 569
 - Parkinson's disease cell death, 570–577
 - rhythmicity in, 7
- Drug abuse:
 - Drosophila* models, 7–8
 - in HIV/AIDS, 712–716
 - methamphetamine/cocaine, 713–715
 - opioid drugs, 715–716
- Drug discovery:
 - neurotrophic factors and, 230–232
- Drug interactions:
 - narcolepsy therapy
 - amphetamines, 98, 100
- Drug-resistant epilepsy, 425–426
- Dyskinesia:
 - Parkinson's disease treatment and classification of, 499
 - levodopa agents, 487
- Electrical stimulation:
 - epilepsy management, 427
- Electrocoagulation model:
 - stroke-related global and focal ischemia, 353–354
- Electroencephalogram (EEG):
 - epilepsy investigation, 405–407
 - narcolepsy therapy
 - dopaminergic neurotransmission and, 94–95
- Eliprodil:
 - stroke management, 357, 359
- Endocrine system:
 - hypocretin/orexin system, 134–135
- Endothelial cells:
 - neuroinflammation, 627
 - pharmacological activation, 633
- Energy expenditure:
 - leptin and, 743–744
- Entrainment properties:
 - circadian rhythms, 5
- Entrainment stimuli:
 - clock neuron synchronization and modulation, 8–9
- Environmental factors:
 - idiopathic Parkinson's disease and, 543–545
 - Tourette's syndrome, 267–269
- Enzymes:
 - in myelin, 609–610
- Ephedrine:
 - as anti-obesity agent, 817–818

- Epilepsy:
- acute seizures and status epilepticus, 427–428
 - alternative therapies, 426–427
 - antiepileptic drugs, 404–405
 - calcium channels, 413–414
 - clinical efficacy, 418
 - clinical prediction markers, 420
 - combination therapy, 423–424
 - development and testing, 418–420
 - felbamate interactions, 414–415
 - GABA_A receptor and, 411–412
 - generalized absence epilepsy, 421
 - localization-related epilepsy, 421–423
 - mechanisms of action, 408–410
 - metabotropic glutamate receptors, 413
 - mixed actions, 414–418, 422
 - secondary generalized epilepsies, 424
 - selection criteria, 421–424
 - sodium channel modulation, 411
 - special population requirements, 424–425
 - synaptic vesicle protein, 414
 - topiramate interactions, 415–418
 - toxicity detection, limitations of, 420–421
 - child-onset absence
 - classification, 405–406
 - classification, 404–405
 - clinical investigation, 405–408
 - diet and, 427
 - drug-resistant, 425–426
 - electrical stimulation therapy, 427
 - focal/localization-related epilepsy
 - classification, 405–406
 - prognosis, 408
 - therapy for, 421, 423
 - future research issues, 428–429
 - generalized absence form
 - therapy options, 421
 - prognosis of, 407–408
 - secondary generalized epilepsy syndrome
 - classification, 405–406
 - therapy options, 424
 - surgical management of, 426
 - temporal lobe epilepsy
 - classification, 405–406
 - surgical treatment, 426
- Epinephrine:
- white adipose tissue innervation, 789–797
- EPO receptor (EPOR):
- stroke therapy and, 377
- ERK1/ERK2 protein kinases:
- tyrosine kinase receptor signal transduction, 243
- Erythropoietin (EPO):
- neuroinflammatory mechanisms, 641
 - stroke therapy and, 377
- Escitalopram:
- autism spectrum disorders, 324–325
- Estrogen response element (ERE):
- leptin receptor expression and, 738–739
- Estrogens:
- neuroinflammation and, 645
 - traumatic brain injury and, 450–451
- Ethosuximide:
- development and testing, 419
 - epilepsy efficacy, 417–418
 - for generalized absence epilepsy, 421
 - T-type calcium channel modulation, 413
- Excessive daytime sleepiness (EDS):
- idiopathic hypersomnia and, 84
 - mazindol therapy, 103
 - narcolepsy, 80–82
 - amphetamines, 90–100
 - drug interactions with, 98, 100
 - molecular targeting of, 93–94
 - side effects, 98
 - bupropion, 103–105
 - caffeine, 104–105
 - dopamine neurotransmitters:
 - substrates, 97–98
 - dopamine neurotransmitters and EEG arousal, 94–97
 - future stimulant development, 105–106
 - mazindol, 103
 - modafinil, 100–103
 - nonamphetamine stimulants, 99–105
 - pharmacological treatment, 90–100
 - selegiline, 104
- Excitatory amino acid transporters (EAATs):
- stroke management, 365–366
- Excitatory mechanisms in stroke:
- AMPA receptor antagonists, 361–363
 - amphetamine and neurotransmitter modulators, 377
 - antiadhesion molecules, 369–370
 - anti-nogo (IN-1) inhibitors, 377–378
 - antioxidants, 371–372
 - apoptosis and caspase inhibitors, 372–373
 - basic characteristics and symptoms, 348–349

- brain injury with
 - classification, 350
 - mechanisms of, 351–353
 - repair approaches, 377–379
- calcium channel blockers, 366–367
- chemokine inhibition, 369
- cytokine inhibition, 368–369
- decahydroisoguinolines, 362
- down-stream approaches, 367–368
- erythropoietin, 377
- global/focal ischemia
 - animal models, 353–354
 - glutamate/glutamatergic receptors, 354–355, 361–366
 - glutamate release inhibitors, 366–367
 - glutamate transporters, 365–366
 - growth factors, 375–377
- GYKI 52466/related benzodiazepines, 362
- inflammatory pathways, 368
- kainate receptor antagonists, 363
- metabotropic glutamate receptors, 363–365
- NBQX/related quinoxalinediones, 361–362
- neuroprotective techniques, 366–373
 - development criteria, 374
- nitric oxide synthase inhibition, 370–371
- NMDA receptor antagonists, 354–359
 - clinical trial data, 358–359
 - competitive/noncompetitive agonists, 356–357
 - glycine site antagonists, 357–358
 - MK-801 compound, 355–356
 - polyamine site antagonists, 357
 - side effects, 359–360
- p38 inhibition, 369
- prevalence and incidence, 349–350
- sodium channel blockers, 367
- sonic hedgehog approach, 378
- stem cell approach, 378–379
- time window issues, 360–361
- upstream techniques, 366–373
- Excitatory neurotransmitters:
 - hypocretin/orexin system, 131–132
- Excitotoxicity cell death:
 - human immunodeficiency virus and, 705–706
- Experimental allergic encephalomyelitis (EAE):
 - natalizumab, 684–685
 - novel therapy for, 678–679
 - pathogenesis, cytokines and, 628–629
 - pathophysiology, 611–612
 - statin therapy, 668
- Extended-release stimulants:
 - attention-deficit hyperactivity disorder therapy, 295
- Extrapyramidal symptoms:
 - Tourette's syndrome therapy, 274–276
- Extrasynaptic receptors:
 - GABA_A receptor structure
 - sedative/hypnotic mechanisms, 180
- Fas-associated death domain (FADD) protein:
 - stroke management, 373
- Fatty acid binding proteins (FABP):
 - protein 2, 603
- Fatty acid metabolisms:
 - overview of, 785–786
- Feeding mechanisms:
 - ghrelin effects, 772–773
 - hypocretin/orexin system, 132–134
 - arousal integration, 144
 - leptin signaling and, 740–743
 - prokineticin regulation, 168–169
- Felbamate:
 - epilepsy efficacy, 417–418
 - ionotropic glutamate receptor modulation, 413
 - for secondary generalized epilepsy, 424
 - target interactions of, 414–415
- Fibroblast growth factors (FGFs):
 - stroke therapy and, 375–377
- FKBP12 protein:
 - multiple sclerosis therapy, 667
- Flenfluramine:
 - as anti-obesity agent, 818
- Fluid extravasation:
 - inflammation and
 - pharmacological activation, 633
- Fluoxetine:
 - autism spectrum disorders, 323–324
 - circadian rhythms and
 - antidepressant effects, 19–20
 - neurogenesis and, 209–210
- Fluvoxamine:
 - autism spectrum disorders, 322–323
 - circadian rhythms and release of, 20
- 4P-PDOT antagonist:
 - melatonin receptor molecular pharmacology, 43–44
 - circadian rhythm modulation, 55–57

- desensitization function, 53
 - in suprachiasmatic nucleus, 49–50
- Free-radical scavengers:
 - traumatic brain injury and, 447
- FTY720 agent:
 - multiple sclerosis therapy, 689
- Functional recovery:
 - stroke therapy and, 375–379
- GABAergic neurons:
 - Parkinson's disease treatment and, 505–506
 - sedative/hypnotic action sites, 184
 - Tourette's syndrome and, 270–273
- Gabapentin:
 - calcium channel modulation, 413–414
 - epilepsy efficacy, 417–418
- Galantamine:
 - dementia disorders and, 463–465
- γ -aminobutyric acid (GABA):
 - GABA_A receptors
 - antiepileptic drugs and, 411–412
 - felbamate, 414–415
 - topiramate, 415–416
 - sedatives:
 - benzodiazepine binding, 190–192
 - pharmacology, 180–181
 - structure, 178–180
 - narcolepsy therapy
 - modafinil, 101–103
 - suprachiasmatic nucleus and, 13–15
 - traumatic brain injury and, 451
- γ -hydroxybutyric acid (GHB):
 - cataplexy therapy, 112
 - disturbed nocturnal sleep therapy, 112
 - sleep paralysis and hypnagogic hallucination therapy, 112
- Gastrointestinal tract:
 - ghrelin modulation, 776
- Gavestinel:
 - stroke management, 359
- GBA polymorphisms:
 - idiopathic Parkinson's disease and, 543
- GBR12909:
 - narcolepsy therapy
 - dopaminergic neurotransmission, 94–95
- Genetic studies:
 - Tourette's syndrome, 266–267
- Genomic screening:
 - Tourette's syndrome, 267
- Ghrelin:
 - acylated peptide hormone, 766–768
- adipocyte and body composition modulation, 774
- agonists/antagonists, 777
- antiproliferative/proliferative effect, 776
- appetite and metabolic regulation, 772–773
- bone effects, 776
- cardiovascular action, 774–775
- expression pattern, 768–769
- gastrointestinal tract function, 776
- growth hormone secretagogues, 769
- growth hormone secretion, 773–774
- immune system modulation, 775
- pancreas function and insulin resistance, 775–776
- peripheral function, 774–776
- receptor
 - constitutive activity, 770–771
 - homologous subfamily, 771–772
- receptor ligands, 766–769
- research history on, 766
- sympathetic nervous system, 774
- thyroid function, 775
- Glatiramer acetate:
 - multiple sclerosis therapy, 676
- Glial cells:
 - human immunodeficiency virus excitotoxicity cell death, 706
 - myelin-forming, 592–593
 - neurotrophins and, 239
- Glial-derived neurotrophic factor (GDNF):
 - amyotrophic lateral sclerosis and, 226–227
 - discovery of, 221–223
 - future research on, 232–233
 - neuroinflammatory mechanisms, 641
 - neuronal maturation regulation, 224
 - pain perception and management, 229
 - Parkinson's disease and, 228–229, 505
- Glial transporters:
 - stroke management, 365–366
- Glucagon-like peptide 1 (GLP1):
 - leptin signaling and feeding regulation, 743
- Glucose:
 - leptin effect on, 746–747
- Glutamate neurotransmitters:
 - neurogenesis and, 207–208
 - Parkinson's disease treatment, 504–505
 - stroke and
 - ischemic brain injury, 351–353
 - NMDA receptor antagonists, 354–355
 - release inhibitors, 366–367

- Tourette's syndrome, 272
 traumatic brain injury and, 449–450
- Glutamatergic receptors:
 autism spectrum disorders
 medications, 331–332
 dementia disorders and, 469–470
 human immunodeficiency virus and
 excitotoxicity cell death, 705–706
 stroke pathophysiology and, 354, 355,
 361–366
 AMPA receptor antagonists, 361–363
 glutamate transporters, 365–366
 kainate receptor agonists, 363
 metabotropic glutamate receptors,
 363–365
- Glutamate transporters:
 stroke management, 365–366
- Glyceroneogenesis:
 lipolysis and thermogenesis, 799–801
- Glycine site antagonists, NMDA receptor:
 stroke management, 357–359
- Glycolipids:
 human neuropathy targeting, 614
- Glycoproteins:
 human immunodeficiency virus, 699,
 701
 human neuropathy targeting, 614
 in myelin, 604–607
- GM6001 inhibitor:
 neuroinflammation and, 633
- Gonadotropin-releasing hormone (GHRH):
 ghrelin effects and, 774
- Gp41 protein:
 human immunodeficiency virus, 699, 701
- Gp120 protein:
 human immunodeficiency virus, 699, 701
 alcohol abuse and, 716
 excitotoxicity cell death, 705–706
 nigrostriatal system and, 709–710
- Gp130 cytokine receptor subunit:
 inflammation mechanisms, 640
- G-protein-coupled receptors (GPCR):
 hypocretin/orexin system, 126–127
 receptors, 128
 melatonin receptor molecular structure,
 41–44
- G proteins:
 ghrelin receptor activity, 770
- Green fluorescent protein (GFP):
 invertebrate neurodegenerative disease
 models
 Parkinson's disease cell death, 570–577
- Growth factors:
 amyotrophic lateral sclerosis and,
 226–227
 inflammation mechanisms, 639–641
 neurogenesis and, 210–211
 neurotrophin structure and, 240
 stroke therapy and, 375–377
- Growth hormone secretagogues (GHS):
 classification of, 766
 ghrelin receptor evaluation, 770
 ghrelin receptor ligands and, 769
- Growth hormone secretion:
 ghrelin effects and, 773–774
- GTS-21 nicotinic agonist:
 dementia disorders and, 468–469
- Guanfacine:
 attention-deficit hyperactivity disorder
 therapy, 299–300
 autism spectrum disorders, 330–331
- Guillain-Barré syndrome:
 myelin pathology, 613–614
- GYKI 52466 antagonist:
 stroke management, 362
- Habit reversal training:
 Tourette's syndrome therapy, 277–278
- Hallucinations:
 hypnagogic hallucinations
 symptoms of, 83
 treatment of, 112
 hypnopompic hallucinations
 symptoms of, 83
 Parkinson's disease and, 502–503
- Haloperidol:
 autism spectrum disorders, 325
 Tourette's syndrome and, 273–276
- HCRT gene:
 hypocretin/orexin system, 127
- HCRTR2 gene:
 hypocretin/orexin system
 narcolepsy and, 137–138
- Hematopoiesis:
 prokineticins and, 170–171
- Hemizyosity:
parkin gene mutations, familial
 Parkinsonism, 531–532
 PINK1 gene mutation and, 533–535
- High-density lipoprotein (HDL):
 antiobesity therapy
 rimonabant and, 827–828
- Highly active antiretroviral therapy
 (HAART):

- HIV neuropharmacology and, 694–695
 methamphetamine/cocaine abuse and, 714–715
 neurodegenerative disease and, 716–718
- High-throughput screening:
 neurodegenerative disease, invertebrate models, 582–583
- Hippocampus:
 hypocretin/orexin system
 plasticity of, 136
 neuronal survival mechanisms, 205–206
- Histamine:
 hypocretin/orexin system
 arousal mechanisms, 142–143
 narcolepsy therapy, 105–106
- Histidine residues:
 sedative/hypnotic binding, 190–192
- HIV-associated dementia (HAD):
 alcohol abuse and, 716
 apoptosis mechanisms, 704–705
 classification, 694–695
 epidemiology and pathogenesis, 695–696
 lipid metabolism and, 707
 methamphetamine/cocaine abuse and, 713–715
 neurodegenerative disease and, 716–718
 neurotransmitters and, 711–712
 nigrostriatal system and, 708–710
 Vpu protein and, 704
- Homologs:
 ghrelin receptors, 771–772
 p75 neurotrophin receptor structure, 241
- Homovanillic acid (HVA):
 Parkinson's disease
 neurochemistry, 481–483
- Hormones:
 neuroinflammation and, 645
- Human autoimmune neuropathies, 613–614
 animal models, 615
- Human immunodeficiency virus (HIV):
 alcohol abuse and, 716
 cholinergic system, 711–712
 clinical features, 694–695
 dementia and, 711–712
 drug abuse and, 712–716
 methamphetamine/cocaine, 713–715
 opioid drugs, 715–716
 excitatory amino acid neurotransmitters, 711
 future neuropharmacology issues, 718
 lipid metabolism alterations, 707
 neurodegenerative diseases and, 716–718
 neuropathology, 695–704
 cell death cascades, 704–707
 apoptosis, 704–705
 excitotoxicity, 705–706
 neural progenitor cells, 706–707
 oxidative stress, 706
 chemokines in, 697–698
 neurodegenerative mechanisms, 699
- neuropharmacology
 features of, 694–695
 future research issues, 718
- neurotoxic proteins, 699–704
 glycoproteins gp120 and gp41, 699, 701
 Nef protein, 703
 neurobiology of, 700
 Rev protein, 704
 Tat protein, 701–703
 Vpr protein, 703
 Vpu protein, 704
 nigrostriatal system, 707–711
 dopamine mediators, 709–711
 pathogenesis, 695
- Human leukocyte antigen (HLA):
 narcolepsy evaluation, 84
 narcolepsy pathophysiology
 immune system and, 85–86
 neuroinflammation and, 626
- Huntington's disease:
 invertebrate models of trinucleotide repeats, 577–579
- 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA):
 multiple sclerosis therapy, 687
- Hydroxyindole-*O*-methyl transferase (HIOMT):
 melatonin production, 40–41
- Hyperserotonin hypothesis:
 autism spectrum disorders, 321–322
- Hyperzine A:
 dementia disorders and, 463
- Hypnagogic hallucinations:
 symptoms of, 83
 treatment of, 112
- Hypnopompic hallucinations:
 symptoms of, 83
- Hypnotics:
 barbiturate-like drugs, 187
 barbiturates, 184–187
 basic principles, 177–178
 benzodiazepines, 187–188
 brain sites of action, 181–184

- GABA_A receptors
 pharmacology, 180–181
 structure, 178–180
 mouse studies, 190–192
 new agents, 188–190
 non-GABA_A receptor agents, 188
 safe development of, 184–190
- Hypocellularity:
 adipocyte proliferative capacity, 797–799
- Hypocretin-1:
 cataplexy therapy, 113–114
 narcolepsy evaluation
 in cerebrospinal fluid, 84
 narcolepsy pathophysiology
 deficiency in, animal models, 86
 narcolepsy therapy
 future research issues, 105–106
- Hypocretin-2:
 history of, 127
- Hypocretin/orexin system:
 afferents, 130
 agonists/antagonists, 128
 arousal, feeding behavior and motivation
 integration, 144–145
 arousal circuitry, 139–144
 cholinergic systems, 143–144
 dopaminergic systems, 143
 histaminergic systems, 142–143
 lateral hypothalamic neurons, 140–141
 noradrenergic systems, 141–142
 serotonergic systems, 142
 autonomic endocrine effects, 134–135
 excitatory neurotransmitters, 131–132
 feeding and metabolism, 132–134
 fiber projections, 129–130
 hippocampal plasticity, 136
 hypocretin cell bodies, 128–131
 hypocretin discovery, 126–127
 lateral hypothalamus, 125–126
 motivation and addiction, 135
 narcolepsy pathophysiology, 136–139
 sleep regulation and, 86–89
 pain and anesthesia, 136
 receptors, 128
 distribution of, 130–131
 at synapses, 130
- Hypothalamic pathway:
 sedative/hypnotic action sites, 182–184
- Hypothalamic-pituitary-adrenal (HPA) axis:
 circadian rhythms and release of, 19–20
- Hypothalamus:
 circadian rhythms and, 23–24
 leptin signaling and and feeding
 regulation, 741–743
- Idiopathic hypersomnia:
 classification of, 84
 modafinil therapy, 100–103
- Idiopathic Parkinson's disease (IPD):
 genetics and, 542–543
parkin gene mutations, 531–532
- IDRA 21 receptor modulator:
 dementia disorders and, 470
- Ifenprodil:
 stroke management, 357
- IGF binding proteins (IGFBPs):
 stroke and, 376–377
- Immediate-release stimulants:
 attention-deficit hyperactivity disorder
 therapy, 294
- Immune system:
 ghrelin modulation, 775
 narcolepsy pathophysiology and, 85–86
- Immunization techniques:
 neuroinflammation modulation, 644–645
- Immunomodulatory therapy:
 multiple sclerosis, 674–676
 novel drug development, 687–688
- Immunoreceptors:
 inflammation and, 631–632
- Indoleamine 2,3-deoxygenase (IDO):
 inflammation mechanisms, 625
 tryptophan metabolism and, 644
- Infection:
 Tourette's syndrome, 268–269
- Inflammation. *See also* Neuroinflammation
 basic principles of, 622–623
 brain immunoreceptors, 631–632
 central nervous system response, 623–624
 blood-brain barrier, 624–625
 costimulatory molecules, 631
 major histocompatibility classes, 631
 neuroinflammation
 antigen-presenting cells, 626
 arachidonic acid pathways, 630
 astrocytes, 627
 blood-derived inflammatory cells, 628
 chemokines, 629–630
 cytokines, 628–629
 endothelial cells, 627
 growth factors, 639–641
 humoral components, 628–630
 immunization approaches, 644–645
 microglia, 626–627

- neurons, 628
- pharmacological modification, 645–646
- radical formation and oxidative damage, 630
- pharmacology, 632–646
 - adenosine pathway purinergic receptor modulation, 643–644
 - antioxidants, 636–637
 - apoptosis modulation, 637–638
 - arachidonic acid/prostaglandin pathways, 634–635
 - cAMP/cGMP modulation, 635–636
 - cannabinoid receptor modulation, 641–642
 - central nervous system migration, 633
 - chimokine-directed approaches, 633–634
 - estrogen/hormones, 645
 - future research issues, 646
 - indoleamine deoxygenase and tryptophan metabolism, 644
 - ion-channel approaches, 642
 - proinflammatory pathway modulation, 638–639
 - statins, 643
 - vitamin D derivatives, 642–643
- toll-like receptors, 631–632
- Inflammatory cascade:
 - traumatic brain injury and, 447–449
- Inflammatory molecules:
 - circadian rhythms and, 21
- Inflammatory pathways:
 - stroke management, 368
- Insulin:
 - ghrelin modulation, 775–776
 - leptin and, 745–746
- Insulin-like growth factor-1 (IGF-1):
 - amyotrophic lateral sclerosis, 226–227
 - ghrelin modulation, 776
 - inflammation mechanisms, 640–641
 - stroke and, 376–377
- Integrins:
 - Tat protein binding, HIV immunodeficiency and, 702–703
- Intercellular adhesion molecule-1 (ICAM-1):
 - inflammation mechanisms, 624–625
 - statin therapy and, 643
 - stroke management, 369–370
- Interference RNA (RNAi):
 - Huntingdon's disease trinucleotide repeats invertebrate model, 577–579
- Parkinson's disease
 - invertebrate models, 573–577
- Interferon β 1b:
 - multiple sclerosis therapy, 674–675
- Invertebrate models:
 - neurodegenerative disease
 - Alzheimer's disease, 579–582
 - Caenorhabditis elegans* system, 568–569
 - Drosophila melanogaster*, 569
 - early research, 567–568
 - future applications, 582–583
 - genetic and molecular pathways, 568
 - Huntington's disease trinucleotide repeats, 577–579
 - Parkinson's disease:
 - dopamine neuron cell death, 569–577
- 2-[¹²⁵I]Iodomelatonin:
 - development of, 39–40
- Ion channels:
 - circadian rhythms and, 9
 - myelin nodal proteins and, 609
 - neuroinflammation and, 642
- Iontropic glutamate receptors:
 - antiepileptic drugs and, 413
- Janus kinase (Jak) gene:
 - leptin secretion and, 737–739
- Jet lag:
 - circadian rhythms, 15
- Jun-N-terminal kinase (JNK):
 - p75 neurotrophin receptor signaling, 246–247
 - Parkinson's disease and, 228–229
- JWS-USC-751X:
 - dementia disorders therapy and, 471–473
- K252a inhibitor:
 - tyrosine kinase receptor blockade, 232
- Kainate receptors:
 - antiepileptic drugs and topiramate, 416–417
 - neurogenesis and, 208
 - stroke and
 - antagonists, 363
 - ischemic brain injury, 351–353
- Ketanserin:
 - narcolepsy therapy
 - GABA inhibition, 101–102
- Kufor Rakeb disease (KRD):
 - familial Parkinson's disease and, 541

- Lamotrigine:
 autism spectrum disorders, 332
 epilepsy efficacy, 417–418
 for secondary generalized epilepsy, 424
 stroke management, 367
- Lateral hypothalamus (LH):
 hypocretin/orexin system, 125–126
 cell bodies, 128–129
 fiber projections, 129–130
 self-stimulation (LHSS), 135
- Lazaroids:
 stroke management, 371–372
- Learning-related survival mechanisms:
 neurogenesis, 204–206
- Lennox-Gastaut syndrome:
 felbamate therapy, 414–415, 418
 therapy options for, 421, 424
- Leptin:
 early research, 733–734
 energy expenditure and, 743–744
 food intake regulation, 740–743
OB gene expression and, 734–736
 peripheral nutrient utilization, 744–748
 receptor expression, 736–739
 signaling inhibition and resistance,
 739–740
- Leucine-rich repeat kinase 2 (LRRK2) gene:
 familial Parkinson's disease and mutation
 of, 536–539
- Levetiracetam:
 drug-resistant epilepsy, 425–426
 synaptic vesicle protein SV2A
 modulation, 414
- Levoamphetamine:
 attention-deficit hyperactivity disorder
 therapy, 297–298
- Levodopa:
 human immunodeficiency virus
 nigrostriatal system and, 710
 Parkinson's disease treatment
 peripheral decarboxylase inhibitor with,
 484–487
 slow-release formulations, 487–488
- Lewy bodies:
 familial Parkinsonism and
 PARK1 and PARK4 mutations,
 527–529
 Parkinson's disease
 invertebrate models of cell death,
 570–577
- Lifestyle factors:
 idiopathic Parkinson's disease and, 544
- Light-dark cycles:
 circadian rhythms, 5
- Lipid metabolism:
 human immunodeficiency virus and, 707
 leptin effect on, 746–747
- Lipolysis:
 adipose tissue signaling and, 802–803
 glyceroneogenesis, 799–801
 leptin effect on, 747–748
- Lipostatic hypothesis, 733–734
- Lisuride:
 Parkinson's disease treatment, 491
- Lithium:
 circadian rhythms and, 15–17
- Long-term potentiation (LTP):
 brain-derived neurotrophic factor
 synthesis and, 224–225
 glutamate receptors and, 470
 hypocretin/orexin system, 136
- Lubeluzole:
 stroke management, 367
- Luteinizing hormone (LH):
 hypocretin/orexin system, 134–135
- Luzindole:
 melatonin receptor inhibition, 39
 in suprachiasmatic nucleus, 49–50
 melatonin receptor molecular
 pharmacology, 43–44
- LY377770 antagonist:
 stroke and
 kainate receptors, 363
- MAdCAM-1:
 inflammation mechanisms, 624–625
- Madopar:
 Parkinson's disease treatment, 484–487
 slow-release formulations, 487–488
- Magnetoencephalography (MEG):
 epilepsy diagnosis, 407
- Major histocompatibility complex (MHC):
 neuroinflammation and, 626–627
 class I/II immunoreceptors, 631
- Matrix metalloproteinases (MMPs):
 neuroinflammation and, 633
 minocycline inhibition, 645–656
 Tat protein promotion of, 703
- Mazindol:
 narcolepsy therapy, 103
- MC4 receptor agonist:
 antiobesity therapy, 828–829
- MCH peptide:
 hypocretin/orexin system, 129

- MCH receptor-1 antagonists:
antiobesity therapy, 829–830
- Melanin-concentrating hormone (MCH):
leptin signaling and feeding regulation, 743
- Melanocortin pathways:
leptin signaling and feeding regulation, 741–743
- Melatonin receptors:
central nervous system
circadian rhythm modulation, 54–57
clock genes and, 50–51
desensitization, 52–53
historical perspective, 38–40
melatonin production, 40–41
molecular pharmacology, 42–44
molecular structure, 41–42
overview, 37–38
regulatory mechanisms, 51–54
signaling mechanisms, 44–46
supersensitization, 54
suprachiasmatic nucleus, 46–54
circadian inputs and outputs, 46–47
receptor localization, signaling, and function, 47–50
as therapeutic targets, 57–61
circadian rhythms, 58
depression, 58–61
sleep, 57–58
circadian rhythm modulation, 54–57
desensitization function, 52–53
regulatory mechanisms, 51–54
sedative/hypnotics and, 188
supersensitization function, 54
in suprachiasmatic nucleus
localization, signaling, and function, 47–50
therapeutic targeting of, 57–61
circadian rhythms, 58
depression, 58–61
sleep, 57–58
white adipose tissue innervation, 794–797
- Memantine:
dementia disorders and, 470
- Membrane activity:
circadian rhythms, 12
- Memory. *See also* Dementia
brain-derived neurotrophic factor synthesis and, 224–225
traumatic brain injury and, 446
- Mesial temporal sclerosis (MTS):
epilepsy and, 405
- Messenger RNA (mRNA):
hypocretin receptor distribution, 130–131
- Metabolism kinetics:
ghrelin effects, 772–773
hypocretin/orexin system, 132–134
leptin gene, 733–734
- Metabotropic glutamate receptors:
neurogenesis and, 208
stroke management, 363–365
- Methamphetamine:
HIV/AIDS and abuse of, 713–715
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP):
parkin gene mutations and, 532
Parkinson's disease pathogenesis and, 546
- Methylphenidate:
attention-deficit hyperactivity disorder, 294–296
autism spectrum disorders, 329–330
narcolepsy therapy, 90–93
- Methylprednisolone:
traumatic brain injury and, 448–449
- Microglia:
neuroinflammation and, 626–627
- Middle cerebral artery occlusion (MCAO):
stroke-related global and focal ischemia, 353–354
- Mild cognitive impairment:
diagnostic criteria, 462
- Mild cognitive motor disorder (MCMD):
HIV neuropharmacology and, 694–696
- Minocycline:
multiple sclerosis therapy, 679
neuroinflammation therapy with, 645–646
- Mirtazapine:
autism spectrum disorders, 331, 334
- Missense mutations:
familial Parkinson's disease and PINK1 gene mutation and, 534–535
- Mitochondrial DNA:
idiopathic Parkinson's disease and, 543
- Mitochondrial dysfunction:
Parkinson's disease pathogenesis and, 545–547
- Mitogen-activated protein kinase (MAPK):
adipose tissue signaling and, 802–803
- Mitoxantrone:
multiple sclerosis therapy, 676–677
- MK-801 antagonist:
human immunodeficiency virus nigrostriatal system and, 709

- stroke and NMDA receptors, 355–356, 361
- Modafinil:
 - attention-deficit hyperactivity disorder therapy, 301
 - narcolepsy therapy, 100–103
 - limits of, 114
 - Parkinson-related sleep disturbance, 504
- Molecular feedback loops:
 - circadian rhythms
 - animal models, 11–12
- Molecular genetics:
 - rhythmicity
 - Drosophila* models, 7
- Molecular targeting:
 - narcolepsy therapy
 - amphetamines, 93–94
- Monoamine neurotransmitters:
 - attention-deficit hyperactivity disorder therapy, 297–298
 - autism spectrum disorders, 331
 - narcolepsy pathophysiology
 - hypocretin/orexin system, 87–89
- Monoamine oxidase inhibitors (MAOIs):
 - cataplexy therapy, 111, 114–115
 - circadian rhythms and
 - antidepressant effects, 19–20
 - Parkinson's disease
 - neurochemistry of, 481–483
 - type B inhibitor (MAO_B), 494–496
- Monoclonal antibodies:
 - multiple sclerosis therapy, 677–679
 - new drug development, 684–687
- Monogenetic Parkinsonism:
 - causative mutations, 527–539
 - genetic mutations in, 525–541
 - non-PARK mutations, 540
 - PARK1 loci, 527–529
 - PARK2 (parkin) mutations, 529–532
 - PARK3 mutations, 541
 - PARK4 loci, 527–529
 - PARK5 (UCH-L1) mutation, 539–540
 - PARK6 (PINK1) mutations, 532–535
 - PARK7 (DJ-1) mutations, 535–536
 - PARK8 (LRRK2) mutation, 536–539
 - PARK9 mutations, 541
 - PARK10 mutations, 541
 - PARK11 mutations, 541
 - Parkinsonism loci, 540–541
 - PARK loci, 526–527
 - potential causative mutations, 539–541
- Monosynaptic H reflex:
 - narcolepsy pathophysiology, 85
- Monotherapies:
 - antiepileptic drugs, 419–420
- Motilin receptor:
 - ghrelin and, 771–772
- Motivation response:
 - hypocretin/orexin system, 135
 - arousal and feeding behavior
 - integration, 144
- Motor fluctuation:
 - Parkinson's disease treatment and classification of, 496–499
 - levodopa agents, 487
- Motor hyperactivity/inattention:
 - autism spectrum disorder, 333–334
- Mouse models:
 - circadian rhythms, 4–5
 - rhythmicity in, 8
 - sedative/hypnotics, 190–192
- Multidrug resistance:
 - drug-resistant epilepsy, 425–426
- Multidrug transporters:
 - drug-resistant epilepsy, 425–426
- Multifocal motor neuropathy (MMN):
 - characteristics of, 614–615
- Multinucleated giant cells (MNGCs):
 - HIV neuropathogenesis and, 697
- Multiple sclerosis (MS):
 - acute relapses
 - treatment of, 672–674
 - chemotherapy agents, 676–677
 - classification of, 671–672
 - immunomodulatory therapies, 674–676
 - monoclonal antibody therapy, 677–678
 - new drug development, 684–687
 - myelin pathology and, 612–613
 - new drug development, 678–679
 - immunomodulator/suppressants, 687–689
 - overview, 683–684
- Muscarinic receptor agonists:
 - dementia disorders and, 465–466
- Myelin:
 - CD9 protein in, 608
 - claudin protein family in, 608
 - CNS proteins, 596–599
 - composition, 592–609
 - lipids, 594–596
 - connexins in, 609
 - 2',3'-cyclic nucleotide
 - 3'-phosphodiesterase, 603–604

- disorders, 611–615
 - autoimmune demyelinating diseases, 611–615
 - axon-glia disruptions, 611
 - experimental allergic encephalomyelitis, 611–612
 - multiple sclerosis, 612–613
- enzymes in, 609–610
- future research issues, 615–616
- glycoproteins in, 604–607
- myelin and lymphocyte protein and plasmolipin, 608
- myelin basic protein, 598–599, 602–603
- paranodal proteins, 609
- peripheral myelin protein-22, 601–602
- PNS proteins, 599–603
- protein 2, 603
- protein locations in, 600
- protein zero in, 599–601
- proteolipid protein, 596–598
- receptors, 610
- structure of, 592
 - molecular organization, 592, 595
 - sheath structures, 592, 594
- tetraspan proteins in, 607–608
- Myelin and lymphocyte protein (MAL):
 - structure and function, 608
- Myelin-associated glycoprotein (MAG):
 - multiple sclerosis and, 613
 - stroke therapy, 377–378
 - structure and function, 604–606
- Myelin basic protein (MBP):
 - peripheral form, 602–603
 - structure and function, 596–598
- Myelin oligodendrocyte glycoprotein (MOG):
 - multiple sclerosis and, 613
 - structure and function, 606–607
- Narcolepsy:
 - evaluation, 83–84
 - cerebrospinal fluid hypocretin-1 assessment, 84
 - histocompatibility human leukocyte antigen testing, 84
 - polysomnography, 83
 - future research issues, 114–115
 - idiopathic hypersomnia, 84
 - overview of, 80
 - pathophysiology, 84–89
 - human leukocyte antigen analysis, 85–86
 - hypocretin/orexin system, 136–138
 - hypocretin/orexin system and sleep regulation, 86–89
 - hypocretin transmission:
 - animal models, 86
 - symptoms analysis, 84–85
 - symptoms of, 80–83
 - cataplexy, 83
 - excessive daytime sleepiness, 82, 84, 90–92
 - hypnagogic/hypnopompic hallucinations, 83
 - sleep paralysis, 83
 - treatment of, 90–100
 - amphetamines, 90–100
 - drug interactions with, 98, 100
 - molecular targeting of, 93–94
 - side effects, 98
 - bupropion, 103–105
 - caffeine, 104–105
 - dopamine neurotransmitters:
 - substrates, 97–98
 - dopamine neurotransmitters and EEG arousal, 94–97
 - future stimulant development, 105–106
 - mazindol, 103
 - modafinil, 100–103
 - monoamine oxidase inhibitor reduction of, 111
 - nonamphetamine stimulants, 99–105
 - selegiline, 104
- Natalizumab:
 - multiple sclerosis therapy, 677–679, 684–685
- Nausea and vomiting:
 - Parkinson's disease treatment and, 500
 - levodopa agents, 486–487
- NBI-31772 molecule:
 - stroke therapy, 376–377
- NBQX antagonist:
 - stroke and, 361–362
- Nerve growth factor (NGF):
 - cognitive function and, 228
 - discovery, 221–222
 - inflammation mechanisms, 641
 - neuronal maturation regulation, 224
 - neuropathies and, 227
 - neurotrophins and, 237–238
 - signaling mechanisms, 239
 - p75 neurotrophin receptor
 - signaling, 246–247
 - structure, 240–241

- pain perception and management, 229
- peripheral nervous system and, 225
- structure of, 240
- tyrosine kinase receptor structure and, 241–242
- Neural progenitor cells:
 - human immunodeficiency virus and, 706–707
- Neural regeneration:
 - traumatic brain injury and, 452–453
- Neurite outgrowth inhibitor (NoGo):
 - stroke therapy, 377–378
- Neuroactive steroids/neurosteroids:
 - traumatic brain injury and, 450–451
- Neuroanatomy:
 - Tourette’s syndrome, 269–270
- Neurochemistry:
 - dementia disorders and, 462–463
 - Parkinson’s disease, 481–483
 - Tourette’s syndrome, 270–273
 - white adipose tissue innervation, 794–797
- Neurodegenerative disease:
 - extra/intracellular protein aggregates and, 644–645
 - HIV neuropathogenesis and, 699, 716–718
 - inflammation mechanisms in, 622–623
 - invertebrate models
 - Alzheimer’s disease, 579–582
 - Caenorhabditis elegans* system, 568–569
 - Drosophila melanogaster*, 569
 - early research, 567–568
 - future applications, 582–583
 - genetic and molecular pathways, 568
 - Huntington’s disease trinucleotide repeats, 577–579
 - Parkinson’s disease:
 - dopamine neuron cell death, 569–577
- Neurogenesis:
 - neurotrophin regulation of, 224
 - prokineticins and, 171–172
 - regulation in adults
 - future research issues, 211–212
 - multiple regulation points, 204
 - overview, 203–204
 - proliferation, 206–211
 - survival, 204–206
- Neuroimaging studies:
 - epilepsy diagnosis, 407
 - stroke management, 360–361
- Neuroinflammation:
 - antigen-presenting cells, 626
 - arachidonic acid pathways, 630
 - astrocytes, 627
 - blood-derived inflammatory cells, 628
 - chemokines, 629–630
 - cytokines, 628–629
 - endothelial cells, 627
 - growth factors, 639–641
 - humoral components, 628–630
 - immunization approaches, 644–645
 - microglia, 626–627
 - neurons, 628
 - pharmacological modification, 645–646
 - radical formation and oxidative damage, 630
 - stroke and
 - ischemic brain injury, 351–353
- Neuroleptics:
 - Tourette’s syndrome and, 273–276
- Neuronal organization:
 - cognitive function and diversity in, 461–463
 - developmental maturation, 224
 - modulation in adults, 224–225
 - narcolepsy therapy, dopaminergic effects, 97–98
 - neurogenesis
 - survival mechanisms, 204–206
 - neuroinflammation, 628
 - neurotrophins and, 239
 - survival and differentiation during development, 222–223
- Neuropathy:
 - human autoimmune neuropathies, 613–614
- Neuropeptides:
 - neurogenesis and, 210–211
- Neuropeptide Y (NPY):
 - ghrelin effects and, 773
 - hypocretin/orexin system and, 132–134
 - leptin signaling and and feeding regulation, 742–743
 - suprachiasmatic nucleus and, 13–15
 - white adipose tissue innervation, 796–797
- Neuroplasticity:
 - traumatic brain injury and, 453–454
- Neuroprotective agents:
 - dementia disorders and, 469
 - Parkinson’s disease and, 504–505
 - stroke management
 - antioxidants, 371–372
 - apoptosis and caspase inhibitors, 372–373
 - development criteria, 374

- downstream approaches, 367–371
 - glutamate release inhibitors, 366–367
 - metabotropic glutamate receptors, 364–365
- Tat protein, 702–703
- traumatic brain injury and, 446–451
 - anti-inflammatory agents, 447–449
 - free-radical scavengers, 447
 - neuroactive steroids/neurosteroids, 450–451
 - neurotransmitter agonists/antagonists, 449–450
- Neurotoxic cascade:
 - traumatic brain injury and, 444–446
- Neurotoxicity:
 - human immunodeficiency virus neuropathogenesis:
 - chemokines and, 698–699
 - proteins, 699–704
 - glycoproteins gp120 and gp41, 699, 701
 - Nef protein, 703
 - neurobiology of, 700
 - Rev protein, 704
 - Tat protein, 701–703
 - Vpr protein, 703
 - Vpu protein, 704
 - Parkinson's disease
 - invertebrate models of cell death, 570–577
- Neurotransmitters:
 - agonists/antagonists
 - traumatic brain injury and, 449–450
 - dementia disorders and, 462–463
 - human immunodeficiency virus dementia and, 711–712
 - in myelin, 610
 - Parkinson's disease
 - neurochemistry, 482–483
 - stroke therapy and modulation of, 377
- Neurotrophic factor 3 (NT-3):
 - discovery of, 221–223
 - neurogenesis regulation, 224
 - neuronal maturation regulation, 224
 - neuropathies and, 227
 - structure of, 240
 - in suprachiasmatic nucleus
 - melatonin receptor actions, 50
- Neurotrophic factor 4/5 (NT-4/5):
 - discovery of, 221–223, 238
 - obesity and weight control, 229–230
 - Parkinson's disease and, 228–229
 - structure of, 240
- Neurotrophic factors (NTFS):
 - adult neurogenesis, 224
 - drug discovery mechanisms, 230–232
 - biological antagonists, 231
 - direct receptor agonists/antagonists, 231–232
 - indirect modulators, 232
 - future research on, 232–233
 - history of, 221–222
 - HIV neuropathology
 - apoptosis and, 705
 - neuroinflammatory mechanisms, 641
 - neuronal function modulation, 224–225
 - neuronal maturation in development, 224
 - neuronal survival and differentiation, 222–224
 - physiological functions of, 222–225
 - therapeutic applications, 225–230
 - Alzheimer's disease and cognitive impairment, 227–228
 - amyotrophic lateral sclerosis, 225–227
 - depression, 229–230
 - obesity and weight control, 229–230
 - pain management, 229
 - Parkinson's disease, 228–229
 - peripheral neuropathies, 227
 - traumatic brain injury and, 452–453
- Neurotrophic hypothesis, 239
- Neurotrophin-3 (NT-3):
 - discovery of, 238
- Neurotrophins:
 - history of, 237–238
 - preference determinants, 242
 - receptors, 238
 - p75-TRK interactions, 247–248
 - signaling, 242–247
 - structure, 240–242
 - retrograde axonal signaling, 248–249
 - signaling functions, 238–239
 - structure, 239–240
- Neurturin (NRTN):
 - discovery of, 221–223
 - Parkinson's disease and, 228–229
- Nev protein:
 - HIV neurotoxicity, 703
- NF- κ B:
 - HIV neuropathology and, 705
- Nicotine:
 - dementia disorders and, 463–465

- Nicotine gum:
Tourette's syndrome, 277
- Nicotinic acetylcholine receptors:
dementia disorders and, 463–465
agonist therapies, 467–468
- Nicotinic receptor agonists:
dementia disorders and, 467–468
neuroprotective aspects of, 469
therapeutic targeting efficacy, 471–473
- Nigrostriatal system:
human immunodeficiency virus and,
707–710
- Nitric oxides:
neuroinflammation and, 630
pharmacology of, 636–637
parkin gene mutations and, 532
traumatic brain injury and, 447
- Nitric oxide synthase (NOS) inhibitor:
stroke management, 370–371
- NMDA (*N*-methyl-D-aspartic acid)
receptors:
antiepileptic drugs and
felbamate, 414–145
topiramate, 416–417
dementia disorders and, 470
human immunodeficiency virus and
alcohol abuse and, 716
excitotoxicity cell death, 705–706
neurogenesis and, 208
neuroinflammation and
antioxidant modulation, 637
stroke and
antagonist development, 354–358
side effects, 359–360
ischemic brain injury, 351–353
traumatic brain injury and, 449–450
- NNC 09-0026 compounds:
stroke management, 367
- Nocturnal sleep studies:
narcolepsy evaluation, 83
- Nonphotic stimuli:
melatonin receptors
clock gene expression, 51
- Noradrenergic agents:
attention-deficit hyperactivity disorder
therapy, 299–301
hypocretin/orexin system
arousal mechanisms, 141–142
- Norepinephrine:
adipocyte proliferative capacity, 798–799
narcolepsy therapy
amphetamine targeting, 92–94
adverse effects, 98
anatomical substrates, 97–98
drug interactions, 98, 100
EEG arousal and, 94–97
- Norepinephrine transporters:
attention-deficit hyperactivity disorder
therapy, 297–298
- NS-649 compound:
stroke management, 367
- Nurr1* gene:
familial Parkinson's disease and, 540
- Obesity and weight control:
adipose tissue
catecholamine signaling mechanisms,
801–803
cell types and depots, 786–789
future research issues, 804
glyceroneogenesis, 799–801
sympathetic nervous system
innervation, 789–797
adipocyte proliferative capacity,
797–799
anterograde tract-testing, SNS to
WAT, 792–797
retrograde tracing neuroanatomical
studies, 790–792
white vs. brown adipocytes, 787–789
- epidemiology, 815–816
- leptin genetics and
early research, 733–734
energy expenditure and, 743–744
food intake regulation, 740–743
OB gene expression and, 734–736
peripheral nutrient utilization, 744–748
receptor expression, 736–739
signaling inhibition and resistance,
739–740
- neurotrophic factors and, 229–230
- pharmacotherapy, 816–821
axokine, 822–824
CCK_A receptor agonists, 830–831
future research issues, 831–833
historic perspectives, 817–818
MC4 receptor agonists, 828–829
MCH receptor-1 antagonists, 829–830
new drug development, 821–831
orlistat, 820–821
PYY3-36 peptide agonists, 831
rimonabant, 824–828
serotonin receptor 5-HT_{2C} agonists, 828
sibutramine, 818–820

- OB* gene:
leptin secretion and expression of, 734–736
- Obsessive-compulsive disorder (OCD):
Tourette's syndrome comorbidity, 266–268, 276–277
- Olanzapine:
autism spectrum disorders, 327–328
Tourette's syndrome therapy, 275–276
- Olfactory bulb granule cell precursors:
neurogenesis and, 211–212
- Oligodendrocyte myelin glycoprotein (OMgp):
structure and function, 607
- Opiates/opioids:
HIV neuropharmacology and, 715–716
Tourette's syndrome, 272–273
- Orlistat:
obesity therapy with, 820–821
- Orthostatic hypotension:
Parkinson's disease treatment and, 500
levodopa agents, 486–487
- Osteogenic protein-1 (OP-1):
stroke and, 376–377
- Output pathways:
suprachiasmatic nucleus, 12–13
- Ovarian disease:
prokineticins and, 170
- Oxidative stress:
familial Parkinson's disease and
DJ-1 gene mutation, 536
human immunodeficiency virus and, 706
methamphetamine/cocaine abuse and, 714–715
Parkinson's disease pathogenesis and, 545–547
- p38 mitogen-activated protein kinase (MAPK) pathway:
stroke management, 369
- p75 neurotrophin receptor:
discovery of, 238
functional interactions, 247–248
signaling mechanisms, 246–247
structure and function, 222–224, 240–241
synaptic function and, 239
- Painful dystonia:
Parkinson's disease treatment and, 499
- Pain perception and management:
hypocretin/orexin system, 136
neurotrophic factors and, 229
Parkinson's disease and, 504
prokineticins and, 166–167
- Pancreas function:
ghrelin modulation, 775–776
- Paranodal proteins:
structure and function, 609
- Parasympathetic nervous system:
white adipose tissue in, 792
- Parkin* gene:
familial Parkinsonism and
PARK2 mutations and, 529–532
idiopathic Parkinson's disease and, 542–543
invertebrate models, 576–577
- Parkinson loci:
familial Parkinson's disease and, 540–541
- Parkinson's disease (PD):
classification, 524–525
etiology and classification, 480
familial (monogenetic) Parkinsonism, 525–541
causative mutations, 527–539
non-PARK mutations, 540
PARK1 loci, 527–529
PARK2 (*parkin*) mutations, 529–532
PARK3 mutations, 541
PARK4 loci, 527–529
PARK5 (*UCH-L1*) mutation, 539–540
PARK6 (*PINK1*) mutations, 532–535
PARK7 (*DJ-1*) mutations, 535–536
PARK8 (*LRKK2*) mutation, 536–539
PARK9 mutations, 541
PARK10 mutations, 541
PARK11 mutations, 541
Parkinsonism loci, 540–541
PARK loci, 526–527
potential causative mutations, 539–541
future treatment options, 505–506
in HIV/AIDS, 718
idiopathic Parkinsonism
classification, 524
environmental factors, 543–545
genetics, 542–543
invertebrate models
dopamine neuron cell death, 569–577
mitochondria and oxidative stress
pathogenesis linked to, 545–547
motor fluctuations and dyskinesia, 497–499
delayed "on," 498–499
diphasic dyskinesia, 499
dose failure, 499

- painful dystonia, 499
- peak-dose dyskinesia, 499
- sudden "off," 498
- wearing off phenomenon, 497–498
- yo-yo-ing, 499
- motor symptom treatments, 484–497
 - amantadine, 496–497
 - anticholinergics, 496
 - antiglutamate agents, 496–497
 - apomorphine, 493–494
 - bromocriptine, 488, 490
 - cabergoline, 491
 - COMT inhibitors, 495
 - dihydroergocryptine, 491
 - dopamine agonists, 488–494
 - dopaminomimetic agents, 484–496
 - entacapone, 496
 - levodopa plus peripheral decarboxylase inhibitor, 484–487
 - levodopa slow-release formulations, 487–488
 - lisuride, 491
 - monoamine oxidase type B inhibitor, 494
 - nondopaminomimetic agents, 496–497
 - pergolide, 490–491
 - piribedil, 493
 - pramipexole, 491–492
 - rasagiline, 495
 - ropinirole, 492
 - selegiline, 494–495
 - stalevo, 496
 - tolcapone, 495
- neurochemistry, 481–483
- neuroprotective therapy, 504–505
- neurotrophic factor therapy and, 228–229
- nonmotor symptoms treatment, 500–504
 - dementia, 502
 - depression and anxiety, 500–502
 - nausea and vomiting, 500
 - orthostatic hypotension, 500
 - psychosis and hallucinations, 502–503
- pharmacotherapy
 - current treatments, 483–484
 - history of, 480–481
- Paroxetine:
 - autism spectrum disorders, 324–325
 - melatonin receptor targeting, 60–61
- Pathogen-associated molecular patterns (PAMPs):
 - neuroinflammation and, 632
- PD 6735 compound:
 - melatonin receptor targeting, 58
- PD90780:
 - nerve growth factor inhibitor, 232
- Peak-dose dyskinesia:
 - Parkinson's disease treatment and, 499
- Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS):
 - Tourette's syndrome, 268–269
- Peptide YY:
 - antiobesity therapy
 - PYY3-36 peptide agonists, 831
 - white adipose tissue innervation, 796–797
- Per1* messenger RNA:
 - benzodiazepines, 20–21
- Pergolide:
 - Parkinson's disease and, 490–491
 - Tourette's syndrome therapy, 276
- Period genes:
 - melatonin receptors, 50–51
- Peripheral myelin protein-22:
 - structure and function, 601–602
- Peripheral neuropathies:
 - neurotrophic factor therapy, 227
- Peripheral nutrient utilization:
 - leptin and, 744–746
- Peroxisome proliferator-activated receptor gamma (PPAR γ):
 - neuroinflammation, 635
- Persephin (PSPN):
 - discovery of, 221–223
- Pervasive developmental disorders (PDDs):
 - aggression/self-injury, 334
 - anxiety and depression, 334
 - interfering repetitive behaviors, 334
 - motor hyperactivity and inattention, 333–334
 - overview, 320–321
 - pharmacology, 321–333
 - adrenergic agonists, 330
 - amantidine, 332
 - antiepileptic drugs, 332–333
 - antipsychotics, 325–328
 - atypical antipsychotics, 326
 - clomipramine, 322
 - clonidine, 330
 - clozapine, 326
 - d-cycloserine, 332
 - dopaminergic medications, 325–330
 - fluoxetine, 323–324

- fluvoxamine, 322–323
- glutamatergic medications, 331–332
- guanfacine, 330–331
- haloperidol, 325
- lamotrigine, 332
- methylphenidate, 329–330
- mirtazapine, 331
- olanzapine, quetiapine, ziprasidone, and aripipazole, 327–328
- pimozide, 325–326
- risperidone, 326–327
- serotonergic medications, 321–325
- sertraline, citalopram, escitalopram, and paroxetine, 324–325
- stimulants, 328–330
- venlafaxine, 331
- syndromes within, 333–335
- Pesticides:
 - idiopathic Parkinson's disease and, 545
- P-glycoprotein (P-gp):
 - drug-resistant epilepsy, 425–426
- Phen-Fen:
 - history of, 818
- Phenobarbital:
 - as antiepileptic drug, 418–419
 - focal/localization-related epilepsy therapy, 421, 423
- Phentermine:
 - as anti-obesity agent, 817–818
- α -Phenyl-*N*-*tert*-butylnitron (PBN):
 - stroke management, 371–372
- Phenytoin:
 - development and testing, 419
 - epilepsy efficacy, 417–418
- Phosphoenolpyruvate carboxykinase (PEPCK):
 - leptin effect on, 746–747
- Phosphatase and tensin (PTEN)-induced putative kinase 1 (PINK1)
 - mutation:
 - familial Parkinson's disease and, 532–535
- Phosphatase and tensin (PTEN) pathway:
 - familial Parkinson's disease genetics and, 532–535
- Phosphodiesterases (PDEs):
 - neuroinflammation and, 635–636
- Phosphoenolpyruvate carboxykinase (PEPCK-C):
 - glyceroneogenesis control, lipolysis and thermogenesis, 800–801
- Phosphoinositol kinase (PI3):
 - tyrosine kinase receptor signal transduction, 243
- Phospholipase C γ -1:
 - tyrosine kinase receptor signal transduction, 242–243
- Photoc response:
 - melatonin receptors
 - clock gene expression, 51
 - suprachiasmatic nucleus and, 14–15
- Physostigmine:
 - dementia disorders and, 464–465
- Pimozide:
 - autism spectrum disorders, 325–326
- Pineal gland:
 - melatonin modulation of circadian rhythms, 55–57
- Piribendil:
 - Parkinson's disease therapy, 493
- Pituitary adenylate cyclase-activating peptide (PACAP):
 - neurogenesis and, 210–211
- PLA₂ enzymes:
 - neuroinflammation
 - arachidonic acid/prostaglandin pathways, 634–635
- Plasmolipin:
 - structure and function, 608
- Polyamine site antagonists, NMDA
 - receptor:
 - stroke and, 357
- Poly-Q repeats:
 - Huntington's disease, invertebrate models, 577–579
- Polysomnography:
 - narcolepsy evaluation, 83
- Potassium channels:
 - circadian rhythmicity and, 9
 - leptin and nutrient utilization, 745–746
 - neuroinflammation and, 642
- PPT-LDT pathway:
 - sedative/hypnotic action sites, 183–184
- Pramipexole:
 - Parkinson's disease treatment, 491–492, 502
- Prazosin:
 - narcolepsy therapy
 - GABA inhibition, 101–102
- Pregabalin:
 - calcium channel modulation, 413–414
 - epilepsy efficacy, 417–418

- Pregnancy:
 antiepileptic drugs in, 424–425
- Presenilin:
 Alzheimer's disease
 invertebrate models, 580–582
- Primary progressive multiple sclerosis (PPMS):
 classification, 671–672
- Progesterone:
 traumatic brain injury and, 450–451
- Progressive multifocal leukoencephalitis (PML):
 neuroinflammation and, 633
- Proinflammatory pathways:
 neuroinflammation and
 modulation of, 638–639
- Prokineticins:
 angiogenesis and reproduction, 169–170
 basic properties, 163, 165
 circadian clock regulation, 167–168
 feeding behavior, 168–169
 future potential, 172
 hematopoiesis, 170–171
 neurogenesis and, 171–172
 pain perception and management, 166–167
 receptors, 164
 smooth muscle contractility regulation,
 166
 structure and function, 164, 166
- Proliferation mechanisms:
 neurogenesis and, 206–211
- Proneurotrophins:
 structure, 239–240
- Pro-opiomelanocortin (POMC):
 antiobesity therapy
 axokine, 823–824
- Prostaglandin E-synthases (PGESs):
 neuroinflammation, 635
- Prostaglandins:
 neuroinflammation and, 630
 pharmacological activation of, 634–635
- Protein 2:
 structure and function, 603
- Protein chemistry:
 GABA_A receptor structure
 sedative/hypnotic mechanisms, 179–180
 myelin, 594–609
- Protein kinase A:
 adipose tissue signaling and, 802–803
- Protein tyrosine phosphatase 1B (PTP1B):
 leptin signaling inhibition and resistance,
 739–740
- Protein zero:
 structure and function, 599–601
- Proteolipid protein (PLP):
 structure and function, 596–598
- Pseudorabies virus (PSV):
 white adipose tissue innervation, 792–797
- Psychosis:
 Parkinson's disease and, 502–503
- Psychostimulants:
 human immunodeficiency virus
 nigrostriatal system and, 710
- Psychotropic drugs:
 neurogenesis and, 210
- Purinergic receptors:
 neuroinflammation
 adenosine pathway and, 643–644
- QT prolongation:
 Tourette's syndrome therapy, 274–276
- Quaaludes:
 structure and function, 187
- Quetiapine:
 autism spectrum disorders, 327–328
 Tourette's syndrome therapy, 275–276
- Quinolinic acid:
 inflammation and, 644
- Quinoxalinediones:
 stroke management, 361–362
- Ramelteon:
 melatonin receptor targeting, 57–58
- Rapid-eye-movement (REM) sleep:
 antidepressants and, 17–18
 ghrelin effects, 774
 melatonin modulation of circadian
 rhythms, 56–57, 58
 monoamine oxidase inhibitor reduction
 of, 111
 narcolepsy pathophysiology, 84–85
 hypocretin/orexin system, 89
- Reactive nitrogen species (RNS):
 neuroinflammation and, 630
 pharmacology of, 636–637
- Reactive oxygen species (ROS):
 neuroinflammation and
 pharmacology of, 636–637
 Parkinson's disease pathogenesis and,
 546–547
- Receptor agonists/antagonists:
 ghrelin receptors, 777
 neurotrophic factors as, 231–232
 traumatic brain injury and, 449–450

- Relapsing remitting multiple sclerosis (RRMS):
 betaseron therapy, 674–675
 classification, 671–672
 multiple sclerosis therapy, 686
- Remacemide:
 stroke management, 358–359
- Repetitive behaviors:
 autism spectrum disorders, 334
- Reproductive function:
 prokineticins and, 169–170
- Retinohypothalamic tract (RHT):
 suprachiasmatic nucleus and, 13–15
- Retrograde axonal signaling:
 neurotrophins, 248–249
- Reverse genetics:
 Parkinson's disease
 invertebrate models, 573–577
- Rev protein:
 HIV neurotoxicity and, 704
- RhoA:
 p75 neurotrophin receptor, 247
- Rhythmicity:
 cellular basis, 8
Drosophila models, 7
- Riluzole:
 stroke management, 367
- Rimonabant:
 antiobesity therapy, 823–828
- Risk factors:
 idiopathic Parkinson's disease,
 542–543
- Risperidone:
 attention-deficit hyperactivity disorder
 therapy, 301
 autism spectrum disorders, 326–327
 Tourette's syndrome therapy,
 274–276
- Ritalin. *See* Methylphenidate
- Rituximab:
 multiple sclerosis therapy, 687
- RJR-2429 nicotinic agonist:
 dementia disorders and, 467–468
- Ropinirole:
 Parkinson's disease treatment, 492
- Rotenone exposure:
 Parkinson's disease and
 invertebrate models, 577
- Rotigotine:
 Parkinson's disease treatment, 505
- Running:
 neurogenesis and, 206
- S20304 agonist:
 melatonin receptors, therapeutic targeting
 of, 59–61
- Satiety signal:
 leptin and, 733–734
- SDZ EAA 494 antagonist:
 stroke management and, 356–357
- Secondary lymphoid tissue:
 neuroinflammation and formation of, 629
- Secondary progressive multiple sclerosis (SPMS):
 betaseron therapy and, 675
 classification, 671–672
- Second-messenger systems:
 Tourette's syndrome, 273
- Secretin:
 hypocretin/orexin system and, 127
- Sedatives:
 barbiturate-like drugs, 187
 barbiturates, 184–187
 basic principles, 177–178
 benzodiazepines, 187–188
 brain sites of action, 181–184
 GABA_A receptors
 pharmacology, 180–181
 structure, 178–180
 mouse studies, 190–192
 new agents, 188–190
 non-GABA_A receptor agents, 188
 safe development of, 184–190
- Seizure disorders:
 acute seizures, 427–428
 classification and definition, 404
 generalized seizures
 classification, 404–405
- Selective serotonin reuptake inhibitors (SSRIs):
 autism spectrum disorders, 322–325,
 333–334
 melatonin receptors, therapeutic targeting
 of, 58–61
 Parkinson's disease and, 501
 sleep effects, 17–18
- Selegiline:
 cataplexy therapy, 111
 human immunodeficiency virus
 nigrostriatal system and, 710
 narcolepsy therapy, 104
- Self-injurious behaviors:
 autism spectrum disorders, 334
- Selfotel:
 stroke management, 358–359

- Serotonin (5-HT) neurotransmitters:
autism spectrum disorders, 321–325
circadian rhythms and
antidepressant effects, 18–20
hypocretin/orexin system
arousal mechanisms, 142
melatonin production, 40–41
neurogenesis and, 209–210
sedative/hypnotics and, 188
suprachiasmatic nucleus and, 14–15
Tourette's syndrome, 272
- Serotonin receptors:
melatonin receptors and, 38–39
serotonin receptor 5-HT_{2A}
sedative/hypnotics and, 190
serotonin receptor 5-HT_{2C} agonist
antiobesity therapy, 828
- Sertraline:
autism spectrum disorders, 324–325
- Serum response element (SRE) pathway:
ghrelin receptor activity, 770
- Sex steroids:
neurogenesis and, 207
- Shc gene:
tyrosine kinase receptor signal
transduction, 243
- SIB-1533A nicotinic agonist:
dementia disorders and, 467–468
- Sibutramine:
as obesity therapy, 818–820
- Sickness behavior:
circadian rhythms and
cytokines and, 21–23
- Signaling mechanisms:
leptin resistance and inhibition, 739–740
melatonin receptors, 44–46
neurotrophic factors, 224–225
neurotrophins, 238–239
tyrosine kinase receptors, 242–244
- Signal transducer and activator of
transcription (STAT):
leptin receptor and expression, 737–739
leptin signaling inhibition and resistance,
739–740
- Sinemet:
Parkinson's disease treatment, 484–487
slow-release formulations, 487–488
- Single nucleotide polymorphism (SNP):
familial Parkinson's disease and
PINK1 gene mutation and, 534–535
- Sipatrigine:
stroke management, 367
- Site-directed mutagenesis:
melatonin receptor molecular structure,
42
neurotrophin structure and, 240
- Sjogren's syndrome:
AF102B agonist and, 466
- Sleep disorders:
antidepressants and, 17–18
cataplexy
defined, 82
narcolepsy pathophysiology, 85
human leukocyte antigen and,
85–86
pharmacological treatment:
future anticataplectics, 113–114
historical overview, 106–107
monoamine oxidase inhibitors, 111
neurotransmission, animal studies,
109–110
receptor subtypes, 110–111
second- and third-generation
antidepressants, 108
sodium oxybate, 112
tricyclic antidepressants, 107–109
- circadian rhythms
chronopharmacology, 15–23
functional importance, 4
future research issues, 23–24
mammalian structural models, 10–13
nonmammalian structural models, 6–10
properties, 4–6
superchiasmatic nucleus period and
phase, 13–15
disturbed nocturnal sleep
treatment of, 112
melatonin receptors
therapeutic targeting, 57–58
narcolepsy
evaluation, 83–84
cerebrospinal fluid hypocretin-1
assessment, 84
histocompatibility human leukocyte
antigen testing, 84
polysomnography, 83
future research issues, 114–115
idiopathic hypersomnia, 84
overview of, 80
pathophysiology, 84–89
human leukocyte antigen analysis,
85–86
hypocretin/orexin system and sleep
regulation, 86–89

- hypocretin transmission
 - animal models, 86
 - symptoms analysis, 84–85
- symptoms of, 80–83
 - cataplexy, 83
 - excessive daytime sleepiness, 82, 84, 90–92
- hypnagogic/hypnopompic
 - hallucinations, 83
 - sleep paralysis, 83
- treatment of, 90–100
 - amphetamines, 90–100
 - drug interactions with, 98, 100
 - molecular targeting of, 93–94
 - side effects, 98
 - bupropion, 103–105
 - caffeine, 104–105
 - dopamine neurotransmitters
 - substrates, 97–98
 - dopamine neurotransmitters and EEG arousal, 94–97
 - future stimulant development, 105–106
 - mazindol, 103
 - modafinil, 100–103
 - nonamphetamine stimulants, 99–105
 - selegiline, 104
- Parkinson's disease and, 503
- sleep paralysis
 - symptoms of, 83
 - treatment of, 112
- Sleep paralysis:
 - symptoms of, 83
 - treatment of, 112
- Small-molecular-weight peptide agonists:
 - cataplexy therapy, 115
- Smoking:
 - idiopathic Parkinson's disease and, 544
- Smooth muscle contractility:
 - prokineticin regulation, 166
- SNCA* gene mutation:
 - familial Parkinsonism and, 527–529
 - idiopathic Parkinson's disease and, 542–543
- Sodium bromide:
 - as antiepileptic drug, 418–419
- Sodium channels:
 - epilepsy and modulation of, 411
 - stroke management and modulation of, 367
- Sodium oxybate. *See* γ -hydroxybutyric acid (GHB)
 - cataplexy therapy, 112
- Sonic hedgehog (Shh) morphogen:
 - stroke therapy, 378
- SPD 502 antagonist:
 - stroke management, 362
- Splice variants:
 - leptin receptor expression and, 738–739
 - tyrosine kinase receptors, 245–246
- Statins:
 - multiple sclerosis therapy, 678–679
 - novel drug development, 687–688
 - neuroinflammation and, 643
- Status epilepticus, 427–428
- Stem cells:
 - stroke therapy, 378–379
 - traumatic brain injury and, 452–453
- Steroids:
 - stroke management, 371–372
 - traumatic brain injury and, 450–451
- Sterol regulatory element binding protein (SREBP1):
 - leptin effect on, 747–748
- Stimulant therapy:
 - attention-deficit hyperactivity disorder, 293–298
 - adverse effects, 298
 - amphetamines, 296–298
 - dexamethylphenidate, 296
 - extended-release methylphenidate, 295
 - immediate-release agents, 294
 - methylphenidate hydrochloride, 294–296
 - autism spectrum disorders, 328–330
- Stress:
 - neurogenesis and, 206–207
- Stroke:
 - AMPA receptor antagonists, 361–363
 - amphetamine and neurotransmitter modulators, 377
 - antiadhesion molecules, 369–370
 - anti-nogo (IN-1) inhibitors, 377–378
 - antioxidants, 371–372
 - apoptosis and caspase inhibitors, 372–373
 - basic characteristics and symptoms, 348–349
 - brain injury with
 - classification, 350
 - mechanisms of, 351–353
 - repair approaches, 377–379
 - calcium channel blockers, 366–367
 - chemokine inhibition, 369
 - cytokine inhibition, 368–369
 - decahydroisoguinolines, 362

- down-stream approaches, 367–368
 erythropoietin, 377
 global/focal ischemia
 animal models, 353–354
 glutamate/glutamatergic receptors,
 354–355, 361–366
 glutamate release inhibitors, 366–367
 glutamate transporters, 365–366
 growth factors, 375–377
 GYKI 52466-related benzodiazepines,
 362
 inflammatory pathways, 368
 kainate receptor antagonists, 363
 metabotropic glutamate receptors,
 363–365
 NBQX-related quinoxalinediones,
 361–362
 neuroprotective techniques, 366–373
 development criteria, 374
 neurotrophic factors and, 229–230
 nitric oxide synthase inhibition, 370–371
 NMDA receptor antagonists, 354–359
 clinical trial data, 358–359
 competitive/noncompetitive agonists,
 356–357
 glycine site antagonists, 357–358
 MK-801 compound, 355–356
 polyamine site antagonists, 357
 side effects, 359–360
 p38 inhibition, 369
 prevalence and incidence, 349–350
 sodium channel blockers, 367
 sonic hedgehog approach, 378
 stem cell approach, 378–379
 time window issues, 360–361
 upstream techniques, 366–373
 Substantia nigra pars compacta (SNc):
 Parkinson's disease neurochemistry and,
 481–483
 invertebrate models of cell death,
 569–577
 Substantia nigra pars reticularis (SNr):
 Parkinson's disease
 neurochemistry, 481–483
 Sulpiride:
 Tourette's syndrome therapy, 276
 Superoxide dismutase (SOD):
 amyotrophic lateral sclerosis and,
 225–227
 stroke management, 371–372
 Supersensitization:
 melatonin receptors, 54
 Suprachiasmatic nucleus (SCN):
 animal models, 10–11
 output pathways, 12–13
 circadian rhythms and
 antidepressant effects, 18–20
 inputs and outputs, 46–47
 period and phase, 13–15
 prokineticin regulation, 167–168
 in cockroach, 10
 melatonin production, 40–41
 melatonin receptors in
 clock gene expression, 50–51
 desensitization function, 52–53
 localization, signaling, and function,
 47–50
 regulatory mechanisms, 51–54
 supersensitization, 54
 therapeutic targeting of:
 sleep mechanisms, 57–58
 Surgical treatment:
 epilepsy, 426
 SVZ compound:
 neurogenesis and, 209–210
 Sympathetic nervous system (SNS):
 adipose tissue, 789–797
 adipocyte proliferative capacity, 797–799
 anterograde tract-testing, SNS to WAT,
 792–797
 retrograde tracing neuroanatomical
 studies, 790–792
 ghrelin effects, 774
 leptin and energy expenditure, 746
 Synapses:
 hypocretins at, 130
 neurotrophins and, 239
 Synaptic vesicle protein SV2A:
 antiepileptic drug modulation, 414
 epilepsy efficacy, 417–418
Synphilin-1 point mutation:
 familial Parkinson's disease and, 540
 α -Synuclein mutations:
 familial Parkinsonism and
 PARK1 and PARK4 mutations,
 528–530
 parkin gene degradation, 532
 Parkinson's disease genetics
 invertebrate models, 570–577
 Tat protein:
 human immunodeficiency virus, 701–703
 alcohol abuse and, 716
 apoptosis and, 705

- excitotoxicity cell death, 705–706
- methamphetamine/cocaine abuse and, 714–715
- nigrostriatal system and, 709
- opioid abuse and, 715–716
- Temperature:
 - circadian rhythms, 5
- Temporal lobectomy:
 - epilepsy, 426
- Temsirolimus (CCI-779):
 - multiple sclerosis therapy, 688
- Teratogenicity:
 - antiepileptic drugs, 424–425
- Δ^9 -Tetrahydrocannabinol:
 - antiobesity therapy, 825–828
 - neuroinflammation and
 - receptor modulation, 641–642
- Tetraspan proteins:
 - structure and function, 607–608
- Therapeutic plasma exchange (TPE):
 - multiple sclerosis acute relapse, treatment of, 673–674
- Thermogenesis:
 - glyceroneogenesis and, 799–801
- THIP agonist:
 - as sedative/hypnotic, 190
- Thyroid function:
 - ghrelin modulation, 775
- Thyrotropin-releasing hormone (TRH):
 - narcolepsy therapy, 105–106
- Tiagabine:
 - epilepsy efficacy, 417–418
 - GABA_A receptor modulation
 - antiepileptic drugs, 412
- Tiaprside:
 - Tourette's syndrome therapy, 276
- Tics. *See* Tourette's syndrome
 - Tourette's syndrome, 264–265, 269–273
 - suppressants, 277
- Timeless gene:
 - melatonin receptors, 51
- Time window paradigm:
 - stroke management, 360–361
- TNF-related apoptosis-inducing ligand (TRAIL):
 - inflammation mechanisms, 625
 - proinflammatory pathway modulation, 639
- Toll-like receptors (TLR):
 - inflammation and, 631–632
- Topiramate:
 - as antiepileptic
 - ionotropic glutamate receptor modulation, 413
 - target interactions, 415–416
 - epilepsy efficacy, 417–418
 - for secondary generalized epilepsy, 424
- Torpedo* electroplax:
 - GABA_A receptor structure
 - sedative/hypnotic mechanisms, 178–180
- Tourette's syndrome:
 - clinical course, 266
 - comorbid disorders, 266
 - diagnostic criteria, 263–264
 - environmental factors, 267–269
 - epidemiology, 266
 - future research issues, 278
 - genetics, 266–267
 - pathophysiology, 269–273
 - neuroanatomical abnormalities, 269–270
 - neurochemical abnormalities, 270–273
 - second-messenger systems, 273
 - phenomenology, 264–265
 - treatment, 273–278
 - adrenergic agonists, 276–277
 - antidopaminergic agents, 276
 - neuroleptics, 273–276
 - nonpharmacological treatments, 277–278
 - tic suppressants, 277
- Toxicity effects:
 - antiepileptic drugs, 420–421
- Tranquilizers:
 - structure and function, 187
- Transforming growth factor- α (TGF α):
 - suprachiasmatic nucleus, 13
- Transforming growth factor- β (TGF β):
 - structure and function, 222–223
- Transforming growth factor family:
 - inflammation mechanisms, 640–641
- Transient receptor potential V1 (TRPV1) receptors:
 - pain perception and management, 229
- Transition metals:
 - Parkinson's disease and
 - invertebrate models, 576–577
- Traumatic brain injury (TBI):
 - characteristics and classification, 443–446
 - future research issues, 454
 - neural regeneration, 452–453
 - neuroplasticity, 453–454
 - neuroprotective agents, 446–451
 - anti-inflammatory agents, 447–449

- free-radical scavengers, 447
 - neuroactive steroids/neurosteroids, 450–451
 - neurotransmitter agonists/antagonists, 449–450
- Tricyclic antidepressants:
 - attention-deficit hyperactivity disorder therapy, 299
 - Parkinson's disease and, 501
- Trihexyphenidyl:
 - Parkinson's disease treatment, 496
- TrkA receptors:
 - cognitive function and, 228
 - neurotrophins and, 238
 - pain perception and management, 229
 - TrkAIII splice variants, 245–246
- TrkB receptors:
 - amyotrophic lateral sclerosis and, 226–227
 - neurotrophic factor expression, 222–224
 - obesity and weight control, 229–230
 - Parkinson's disease and, 228–229
 - splice variants, 245–246
 - synaptic function and, 239
- TrkC receptors:
 - neuropathies and, 227
 - splice variants, 245–246
- Tryptophan:
 - inflammation and metabolism of, 644
- Tumor necrosis factor- α (TNF α):
 - human immunodeficiency virus nigrostriatal system and, 710
- Tumor necrosis factor (TNF):
 - neuroinflammation
 - proinflammatory pathway modulation, 638–639
 - p75 neurotrophin receptor structure and, 240–241
- Tyrosine kinase receptors. *See also* specific receptors, e.g. TrkA receptor
 - functional interactions, 247–248
 - neurotrophic factors and, 231–232
 - neurotrophins and, 238
 - signaling mechanisms, 242–246
 - preference determinants, 242
 - protein binding, 243–245
 - signal transduction pathways, 242–243
 - splice variants and, 245–246
 - structure of, 241–242
- Ubiquitin carboxyl terminal hydrolase L1 (UCH-L1) mutation:
 - familial Parkinson's disease and, 539–540
- Uncoupling protein:
 - adipose tissue cell types and depots, 786–789
- Upstream techniques:
 - stroke management, 366–373
- Uridine-diphosphoglucose-*N*-acetylglucosamine (UDP-GlcNAc):
 - leptin secretion and, 736
- Vagal nerve stimulation (VNS):
 - epilepsy management, 427
- Valproate:
 - development and testing, 419
 - epilepsy efficacy, 417–418
 - for secondary generalized epilepsy, 424
- Vanilloid receptors:
 - tyrosine kinase receptor signaling, 245
- Vascular cell adhesion molecule-1 (VCAM-1):
 - inflammation mechanisms, 624–625
- Vascular endothelial growth factor (VEGF):
 - prokineticins and, 169–170
- Vascular monoamine transporter (VMAT):
 - narcolepsy therapy
 - amphetamine targeting, 94
- Venlafaxine:
 - attention-deficit hyperactivity disorder therapy, 301
 - autism spectrum disorders, 331
- Ventral tegmental area (VTA):
 - Parkinson's disease neurochemistry and, 481–483
- Ventrolateral preoptic nucleus (VLPO):
 - narcolepsy therapy
 - modafinil, 102–103
- Vesicular monoamine transporter 2 (VMAT2):
 - attention-deficit hyperactivity disorder therapy, 297–298
- Vigabatrin:
 - epilepsy efficacy, 417–418
 - GABA_A receptor modulation, 412
- Vitamin D:
 - neuroinflammation and, 642–643
- Vitamin D receptor agonists:
 - neuroinflammation and, 643
- Vitamin E:
 - neuroinflammation and
 - antioxidant modulation, 637
- Vitamins:
 - idiopathic Parkinson's disease and, 544–545

- VLPO nucleus:
 sedative/hypnotic action sites,
 182–184
- Voltage-activated sodium channels:
 epilepsy and modulation of, 411
- Vpr protein:
 HIV neurotoxicity and, 703
- Vpu protein:
 HIV neurotoxicity, 704
- White adipose tissue (WAT):
 classification, 786–789
 glyceroneogenesis control, lipolysis and
 thermogenesis, 799–801
 molecular features, 787–789
 sympathetic nervous system innervation,
 789–797
 anterograde tract-tracing, 792–797
 retrograde neuroanatomical studies,
 790–792
- Withdrawal:
 antiepileptic drugs, 419–420
- Yellow fluorescent protein (YFP):
 Huntingdon's disease trinucleotide repeats
 invertebrate model, 577–579
- YM-872 antagonist:
 stroke management, 361–362
- Yo-yo-ing dyskinesia:
 Parkinson's disease treatment and, 499
- Zeitgeber* time:
 circadian rhythms and, 20–21
 narcolepsy pathophysiology
 hypocretin/orexin system, 88–89
- Ziprasidone:
 autism spectrum disorders, 327–328
 Tourette's syndrome therapy, 275–276
- Zonisamide:
 T-type calcium channel modulation, 413